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ABSTRACT OF DISSERTATION
Bivariate Generalization of the Time-to-Event Conditional Reassessment Method
with a Novel Adaptive Randomization Method
Phase I clinical trials in oncology aim to evaluate the toxicity risk of new therapies
and identify a safe but also effective dose for future studies. Traditional Phase I trials
of chemotherapies focus on estimating the maximum tolerated dose (MTD). The
rationale for finding the MTD is that better therapeutic effects are expected at higher
dose levels as long as the risk of severe toxicity is acceptable. With the advent of a
new generation of cancer treatments such as the molecularly targeted agents (MTAs)
and immunotherapies, higher dose levels no longer guarantee increased therapeutic
effects, and the focus has shifted to estimating the optimal biological dose (OBD).
The OBD is a dose level with the highest biologic activity with acceptable toxicity.
The search for OBD requires joint evaluation of toxicity and efficacy. Although
several seamleass phase I/II designs have been published in recent years, there is not
a consensus regarding an optimal design and further improvement is needed for some
designs to be widely used in practice.
In this dissertation, we propose a modification to an existing seamless phase I/II
design by Wages and Tait (2015) for locating the OBD based on binary outcomes,
and extend it to time to event (TITE) endpoints. While the original design showed
promising results, we hypothesized that performance could be improved by replacing
the original adaptive randomization stage with a different randomization strategy. We
proposed to calculate dose assigning probabilities by averaging all candidate models
that fit the observed data reasonably well, as opposed to the original design that
based all calculations on one best-fit model. We proposed three different strategies to
select and average among candidate models, and simulations are used to compare the
proposed strategies to the original design. Under most scenarios, one of the proposed
strategies allocates more patients to the optimal dose while improving accuracy in
selecting the final optimal dose without increasing the overall risk of toxicity.
We further extend this design to TITE endpoints to address a potential issue of
delayed outcomes. The original design is most appropriate when both toxicity and
efficacy outcomes can be observed shortly after the treatment, but delayed outcomes
are common, especially for efficacy endpoints. The motivating example for this TITE
extension is a Phase I/II study evaluating optimal dosing of all-trans retinoic acid
(ATRA) in combination with a fixed dose of daratumumab in the treatment of re-
lapsed or refractory multiple myeloma. The toxicity endpoint is observed in one cycle
of therapy (i.e., 4 weeks) while the efficacy endpoint is assessed after 8 weeks of treat-
ment. The difference in endpoint observation windows causes logistical challenges in
conducting the trial, since it is not acceptable in practice to wait until both outcomes
for each participant have been observed before sequentially assigning the dose of a
newly eligible participant. The result would be a delay in treatment for patients and
undesirably long trial duration. To address this issue, we generalize the time-to-event
continual reassessment method (TITE-CRM) to bivariate outcomes with potentially
non-monotonic dose-efficacy relationship. Simulation studies show that the proposed
TITE design maintains similar probability in selecting the correct OBD comparing to
the binary original design, but the number of patients treated at the OBD decreases
as the rate of enrollment increases.
We also develop an R package for the proposed methods and document the R func-
tions used in this research. The functions in this R package assist implementation
of the proposed randomization strategy and design. The input and output format
of these functions follow similar formatting of existing R packages such as ”dfcrm”
or ”pocrm” to allow direct comparison of results. Input parameters include efficacy
skeletons, prior distribution of any model parameters, escalation restrictions, design
method, and observed data. Output includes recommended dose level for the next
patient, MTD, estimated model parameters, and estimated probabilities of each set
of skeletons. Simulation functions are included in this R package so that the proposed
methods can be used to design a trial based on certain parameters and assess per-
formance. Parameters of these scenarios include total sample size, true dose-toxicity
relationship, true dose-efficacy relationship, patient recruit rate, delay in toxicity and
efficacy responses.
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Continual Reassessment Method
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Chapter 1 Introduction
Phase I trials in oncology
Cancer remains a leading cause of death in the US. According to the National Can-
cer Institute (NCI) estimates, there will be about 1.7 million new cancer cases and
600,000 cancer related death in 2017 [1, 2]. The heavy burden of cancer on families,
healthcare systems, and society demands rapid development of better therapies. Po-
tential solutions to this public health issue include better cancer prevention programs
and more advanced cancer treatments. Clinical trials are one of the most important
steps in developing novel treatments against cancer. Not only cancer patients may
benefit from the novel treatments developed through clinical trials, crucial informa-
tion about the mechanism of cancer is also be obtained from clinical trials. Such
information will also give new insights about cancer prevention.
Although the first recorded clinical trial dates back to the biblical descriptions
in 500 BC., the study of clinical trial design is a very new field of research. The
first controlled trial was conducted by Dr. James Lind in 1747. The concept of
placebo effect arrived in the early 1800s and the first double blind controlled trial
was conducted in 1943 [3, 4]. Statistics were not incorporated in clinical trials until
late 1940s when the first randomized trial was proposed and implemented by Sir
Bradford Hill [5].
Modern drug development involves multiple clinical trials which are conventionally
divided into three Phases, Phase I, II, and III. Phase I is commonly known as the
“first in human studies” as it is the first time a new drug is being tested on human
subjects. Phase I trials are especially crucial in developing oncology drugs because
of the inherent risks of cancer treatments [6]. Prior to phase I studies, extensive
research must be conducted to provide rationale of potential therapeutic benefits.
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Pharmacokinetics and pharmacodynamics (PKPD) models need to be established
from non-human subjects. However, pre-clinical predictions are not always accurate
and can only provide an estimate of the recommended dose range. Several doses or
administration schedules may be proposed from pre-clinical studies, and the selection
of optimal dosing schedule can only be obtained through trials on human subjects.
In general, the goal of phase I trial is to evaluate the safety of a new drug on human
subjects, establish the first human PKPD model, and select the most promising dose
for further research.
The concept of phase I trials arose from the development of chemotherapies since
the 1940s [7]. The primary goal of phase I trial for chemotherapy drugs is to find
the maximum tolerated dose (MTD) beyond which the consequence of toxicity out-
weighs potential benefits. The therapeutic effects of chemotherapies are achieved by
impairing the process of DNA replication or cell division. Chemotherapy drugs are
classified as cytotoxic since they are toxic to all living cells. Because cancer cells are
constantly dividing, they are more likely to be affected than normal cells. Therefore,
for chemotherapies, the MTD is the most promising dose for therapeutic benefits.
The development of novel cancer treatments, such as molecularly targeted agents
(MTAs) and immunotherapies, is changing the landscape of phase I trials. These
treatments act through different mechanisms than traditional chemotherapies. MTAs
are designed to target molecules on the pathway of cancer growth or self-repair. Im-
munotherapies enhance or assist the immune system to target cancer cells. These
novel methods of cancer treatments are referred to as non-cytotoxic or cytostatic,
since their therapeutic effects are not achieved through directly attacking living cells.
For cytostatic agents, it is not always appropriate to assume that higher doses will
increase the probability of a positive response. Therefore, the aim for trials of cyto-
static agents is usually to identify the optimal biologic dose (OBD) which is defined as
the dose with the highest probability of efficacy and acceptable toxicity. Dose-finding
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trials aiming to select the OBD require novel dose-finding designs.
A well designed phase I trial not only provides a justified dosing schedule for
future development, but also directly impacts the patients participating in those
phase I studies. In modern clinical trials, patient safety and benefits deserve the
highest priorities in the trial design. The population for Phase I cancer trials are
patients who have often exhausted existing treatment options. The enrolled patients
usually have advanced stage cancer, and possibly deteriorated health conditions due
to exposure to prolonged treatments. Treating these patients either too aggressively
or too conservatively raises ethical concerns. Therefore, phase I trials need to be
carefully designed to minimize the risk and maximize potential benefits.
In the remaining sections of this chapter, we first introduce traditional early phase
dose-finding designs, including rule-based designs and model based designs, as well
as the expansion cohort approach. After the traditional designs, we review recently
published literature on seamless phase I/II designs for finding OBD and discuss the
rationale for the research in this dissertation.
1.1 Dose-finding trials in oncology
A dose-finding trial aims to select one dose level of a new agent from a set of I
pre-defined doses D = {d1, d2 . . . , dI}. If it is plausible to assume that efficacy mono-
tonically increases with dose levels, then the goal is to find the MTD; otherwise, if
it’s possible for efficacy to plateau or decrease after an intermediate dose, the OBD
need to be selected. Suppose toxicity and efficacy are observed through binary end-
points Yj and Zj, where j is the index of patients. Toxicity data are observed as
the grade of adverse events (AEs) according to the Common Terminology Criteria
for Adverse Events v4.0 (CTCAEv4) [8] and dichotomized into dose-limiting toxicity
(DLT) or non-DLT. Generally, a grade 3 or 4 AE will be classified as DLT and lower
grade AEs are non-DLT. Efficacy is observed through pre-defined measures such as
3
response evaluation criteria in solid tumors (RECIST), proportion of target molecule
inhibition, or PD/PK measures.
Yj =

0, if no DLT observed
1, if DLT observed
, and Zj =

0, if no efficacy response
1, if observe efficacy response
The dose received by the jth patient is denoted by xj ∈ D, and the length of time
a patient has been treated by the testing drug is denoted by tj. The data observed
from the first n patients can be denoted by
Ωn = {(xj, tj, yj, zj)|j = 1, 2, . . . , n}.
If the outcomes can be observed within a reasonable time frame, the follow-up time
tj may be ignored by the trial design. For example, the original CRM design only
requires the toxicity data, Ωn = {(xj, yj)}, whereas time-to-event (TITE) CRM adds
the time variable Ωn = {(xj, yj, tj)}
Traditional dose-finding designs assume that patients treated at higher dose levels
will have a larger probability of observing a toxicity response but also better chance
of having therapeutic effects. Therefore, the goal for traditional designs is to find
the MTD, defined as the dose level i = 1, 2, . . . , I with DLT probability closest to a
pre-specified level ξ, that is
MTD = arg min
i
|Pr(Y = 1|di)− ξ|.
Conventionally, patients are enrolled and treated in cohorts of three, so ξ = 33% is
often used in phase I oncology trials.
1.2 Rule-based designs
Rule-based designs determine dose level for the next cohort based on a pre-defined
algorithm. The first cohort of patients are typically tested at the lowest dose level.
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The dose level for the next cohort is determined by the toxicity outcomes of the
current cohort. If the proportion of patients experience DLT is less than a pre-
specified value, the next cohort will receive the next higher dose level; otherwise, the
dose level will decrease or stay at the current level. The trial stops when either the
quota for sample size is reached or MTD is concluded. Patients are conventionally
enrolled in cohorts of 3, so these designs are also referred to as the ‘3+3’ designs. As
an example, figure (1.1) shows a standard ‘3+3’ escalation design.
Figure 1.1: Standard ‘3+3’ escalation design
There are several variations of the standard escalation design. For example, the
up-and-down designs allow de-escalation based on the outcomes of the most recent
cohort [9, 10]. Alternatively, a two-stage design can be used in order to treat less
patients at sub-therapeutic doses. In a two-stage design, cohorts of one patient may
be used for escalation, and the trial switches to different design after the first DLT is
observed. Other designs such as the accelerated titration designs, biased coin design
and its variations, and pharmacologically guided designs are also available for Phase
I dose-finding trials [11–13]. Methods proposed in this dissertation are referred to
as model-based designs rather than rule-based. Therefore, we will not introduce the
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other rule-based designs in further details. A comprehensive review of dose escalation
designs can be found in an article by LeTourneau [14].
1.3 Model-based designs
Model-based designs are built on underlying statistical models that describe the dose
toxicity relationship. A major advantage of model-based designs is that all observed
data are utilized, as opposed to rule-based designs where the dose assignment is
determined by outcomes from the most current cohort.
CRM: The continual reassessment method (CRM) [15] is the first model-based
design proposed for adoption in phase I trials. The CRM uses a one-parameter model
to estimate the dose-toxicity curve. Note that the model only needs to reasonably
well approximate the true dose-toxicity curve around the targeted toxicity level. Dose
assignment by CRM is based on the estimated dose-toxicity curve rather than a set
of pre-defined rules. After its original proposal, the CRM design gained popularity
among biostatisticians and several CRM-related designs were proposed to handle
more complex situations [16]. The original CRM design assumes a dose-toxicity
model [15] piY (xj) = F (xj; θ), where piY denotes the probability of observing a DLT
response from the jth patient, and xj ∈ D corresponds to the dose assigned to the jth
patient. Commonly used dose-toxicity models include the empirical model
F (x, θ) = xexp(θ),
the logistic model
F (x, θ) =
exp(a0 + θx)
1 + exp(a0 + θx)
,
and the hyperbolic tangent model
F (x, θ) =
(
tanhx+ 1
2
)θ
.
The original CRM design was proposed using a Bayesian approach, by which the
prior distribution g(θ) needs to be specified before the trial. For example, we can use
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the empirical model and normal prior distribution, θ ∼ N(θˆ0, σ2θ), where θˆ0 and σ2θ
are prior mean and variance, respectively.
The CRM design requires a set of ‘skeletons’ to be specified prior to the trial.
Denoted by p = {p1, p2, . . . , pI}, ‘skeletons’ are our initial guesses of the probabilities
of observing DLT at each dose level. The dose labels dis are obtained by solving
pi = F (di, θˆ0).
For instance, suppose a study is designed to select a dose from 10, 20, 35, 50,
80 (mg/day). p3 = 40% is the initially guessed DLT rate at the 3
rd dose level (35
mg/day). Using the empirical model F (x; θ) = xexp(θ) with prior θˆ0 = 0, we can
obtain d3 by solving p3 = F (d3; θˆ0) = d
exp(θˆ0)
3 ⇒ d3 = 0.4. Let xj denotes the dose
that the jth patient receives. For example, x2 = d3 means that the second enrolled
patient is treated at the third dose level.
The posterior mean of θ after observing the outcomes from the first n patients
can be estimated by
θˆn =
∫
θLn(θ)g(θ)dθ∫ Ln(θ)g(θ)dθ , (1.1)
where Ln(θ) is the likelihood function:
Ln(θ) =
n∏
j=1
{F (xj, θ)}yj{1− F (xj, θ)}1−yj (1.2)
The original CRM design will treat the next patient at the current estimated
MTD given all accrued patient data.
MTD = arg min
x∈D
|F (x, θˆn)− ξ|. (1.3)
Certain dose-assigning restrictions may apply to override the estimated MTD to en-
sure patient safety. Commonly used restrictions include dose-skipping and coherence.
Dose skipping is defined as assigning a patient to the ith dose level before the (i−1)th
dose level is tested. Coherence refers to avoiding dose escalation immediately after
observing a DLT response from the current patient as well as de-escalation immedi-
ately after a non-DLT response. When properly calibrated [17], the CRM design can
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be used in conjunction with algorithmic designs. For example, a trial may start with
a rule-based design and switch to the CRM when the first DLT case is observed.
Previous studies have repeatedly shown that CRM designs have better accuracy
in estimating the MTD and allocate more patients to the MTD than rule-based de-
signs [18–20]. Rule-based designs often under-estimate the MTD while assigning a
large portion of patients to sub-therapeutic dose levels. Despite these poor oper-
ating characteristics, ‘3+3’ designs are still the most commonly utilized designs in
phase I trials due to their long history of application and straightforward approaches.
However, the use of model-based designs are gradually increasing [21, 22] as clinical
investigators start realizing the statistical superiorities of model-based designs.
TITE-CRM: Traditional CRM is appropriate when the outcomes can be ob-
served within a reasonable short follow-up interval since the design requires each
patient to be completely followed before dose for the next patient can be assigned.
When delays are expected for toxicity outcomes, the traditional CRM design may
result in impractically long trial duration. Cheung and Chappell [23] proposed an
extension to the CRM that incorporates partial information from patients who are
still under observation for outcomes. This method is referred to as the time-to-event
(TITE) CRM.
TITE-CRM incorporates partial follow-up information by using TITE outcomes,
as opposed to traditional CRM that uses simple binary outcomes. Let tj,n denotes the
follow-up time and Yj,n denotes the current outcome for the j
th patient by the time the
(n+ 1)th patient is enrolled. Note that the value of Yj,n may change from 0 to 1 as n
increases, indicating toxicity/efficacy effects manifest after certain time point. Toxic-
ity is monitored by a weighted dose-toxicity model piY (di, w) = G(di, τ, θ) = τF (θ, di).
The weight τ depends on the length of time a subject has been treated. If a toxicity
response is observed, then the observation is given full weight τj = 1; otherwise, the
weight monotonically increases with the length of follow-up tj,n. A commonly used
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option is the linear weight function τj = tj,n/T . There are other options for weight
function but this linear function is simple and performs well in simulations [23]. Using
weighted power model, the likelihood function can be expressed as
Lw(θ|Ωn) =
n∏
j=1
{τj(tj,n, T ) · pexp(θ)xj }Yj,n{1− τj(tj,n, T ) · pexp(θ)xj }1−Yj,n .
Model estimation and dose assignment can be done similarly to the CRM. The poste-
rior mean of model parameter can be calculated from the weighted likelihood function:
θˆwn =
∫
θLwn (θ)g(θ)dθ∫ Lwn (θ)g(θ)dθ . (1.4)
The MTD can be expressed as
MTD = arg min
x∈D
|F (x, θˆwn )− ξ|. (1.5)
Other model-based designs: There are many other model-based designs avail-
able for Phase I oncology trials. For example, the escalation with overdose control
(EWOC) [24] is essentially a modified CRM design with additional measures to re-
duce the chance of exposing patients to excessively high dose levels. Another example
is the use of isotonic model [25] in Phase I designs. The isotonic model design differs
from CRM designs by using non-parametric models to avoid misspecification of the
dose-toxicity curve.
A recently proposed design combines advantages of rule-based and model-based
designs. The Bayesian Optimal Interval (BOIN) design is easy to implement similar
to the 3+3 design, but is more flexible for choosing the target toxicity rate and cohort
size and yields a substantially better performance that is comparable to that of more
complex model-based designs [26]. Unlike rule-based designs that estimate the MTD
only using data from the most recent cohorts, the BOIN design uses isotonic regression
to utilize data collected over the entire trial.
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1.4 A new generation of cancer treatments and novel Phase I/II designs
Cytotoxic agents are drugs that achieve tumor shrinkage through non-selective at-
tack of living cells, whereas cytostatic agents target tumor growth pathways without
directly attacking cells. Because the mechanism of cytotoxic and cytostatic agents
are fundamentally different, the paradigm of trial design needs to be adjusted. Tra-
ditionally, the dose-finding trials in Phase I aim to select the MTD, assuming the
MTD is the most promising dose for therapeutic effect. For some cytostatic agents,
higher doses will not increase and could possibly decrease efficacy after exceeding the
intermediate dose [27].
Cytostatic agents are often used in combination with cytotoxic treatments in
order to achieve optimal results. For example, angiogenesis is an important path-
way in tumor growth, and upregulated VEGF/VEGFR expression is an established
biomarker on this pathway. The VEGFR antibody DC101 in combination with vin-
blastine demonstrated full and sustained regression of large, established tumors in
neuroblastoma xenograft models [28]. Several Phase III trials confirmed the effects
of bevacizumab, an agent targeting VEGFA, when combined with platinum-based
chemotherapy in patients with nonsmall cell lung cancer (NSCLC) or platinum-
sensitive recurrent ovarian primary peritoneal, fallopian tube cancer [29–32].
Even though cytostatic agents are often less toxic than traditional chemotherapies,
toxicity still needs to be closely monitored in early Phase trials. Severe adverse events
are still possible and unpredictable before tested in patients. For example, unexpected
severe toxicity effects in patients with MBC were observed when testing cetuximab
(an effective EGFR antibody) in combination with cisplatin and topotecan [33,34].
Therefore, trial designs involving cytostatic agents need to model monitor toxicity
and efficacy at the same time, which are conventionally the objectives of two trial
phases. Traditional designs may adopt the expansion cohort approach to collect
additional efficacy data in phase I settings. Expansion cohorts are originally intended
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to mitigate the limitation of small sample size in Phase I studies and verify the selected
dose before moving on to Phase II. By enrolling and treating additional patients at
the last recommended dose, more information regarding safety, efficacy, PD/PK can
be obtained, and patient enrichment may be enhanced. The sample size of expansion
cohort is not based on statistical considerations, and may vary from a few to dozens
of patient. A review of 611 unique Phase I cancer trials found that about 25% of the
trials included an expansion cohort, and trials were significantly more likely to use an
expansion cohort if they were more recent, multi-center, or testing a non-cytotoxic
agent [35]. However, this approach is not appropriate when dose-efficacy curves are
not monotonic since the optimal dose may be under the MTD.
As an alternative to expansion cohort, a two-step approach can be adopted in
which the MTD is located first and then search for OBD using efficacy endpoints.
Hoering et al. suggested randomizing patients to three dose levels: the MTD, and
the two nearby doses [36]. A similar approach by Yin et al. [37] is to identify toxicity
upper bound of the searching range and determine OBD through dose de-escalation.
In recent years, there is a trend to integrate Phase I and Phase II trials into
one seamless process. A seamless phase I/II trial can not only better address the
issue of non-monotonic dose-efficacy curves, it also saves resources and accelerates
the drug development process. Many new Phase I/II designs have been published
[38–47]. A bivariate CRM design to incorporate efficacy was proposed by Braun.
This design extended the original CRM to a bivariate CRM (bCRM) through a
conditional probability model for efficacy and toxicity, but it was not designed to
deal with non-monotonic dose-efficacy curves. Thall and Cook proposed an adaptive
Bayesian dose-finding design based on a set of efficacy-toxicity trade off contours that
partition the two-dimensional outcome probability domain to find the OBD. Bekele
and Shen incorporates a continuous activity outcome with binary toxicity outcomes
into the dose-finding design. Yin et al. jointly modeled toxicity and efficacy using a
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bivariate binary model and considered the correlation between toxicity and efficacy. A
design using continuation-ratio model was proposed by Zhang et al. to model toxicity
and efficacy as a trinomial endpoint: no efficacy and no toxicity, efficacy without
toxicity, and toxicity. Yuan and Yin proposed a design that jointly models toxicity
and efficacy as time to event outcomes to address the issue of censoring at decision-
making time. Wages and Tait proposed a seamless Phase I/II design that accounts
for non-monotonic dose-efficacy relationships by fitting multiple efficacy models and
using posterior model probabilities to select the best-fit efficacy model. This design
combines features of the CRM design and order restricted inferences (Partial Order
CRM) [48]. Riviere et al. employed a logistic model with a plateau parameter
to capture the increasing-then-plateau feature of the dose-efficacy relationship. In
addition, there are non-parametric approaches in the literature in order to avoid
misspecification of the dose-toxicity curve. Gasparini and Eisele proposed to use a
flexible product-of-beta prior in a curve-free model. Zang et al. introduced a non-
parametric approach that uses the isotonic regression to estimate the OBD, and a
semi-parametric approach by assuming a logistic model only around the current dose.
A comprehensive overview of Bayesian designs for Phase I-II clinical trials is provided
by Yuan, Nguyen, and Thall (2016) [49].
The research of seamless phase I/II designs is a recent topic and novel designs are
still being developed. Although many designs have demonstrated better operating
characteristics than traditional approaches, there is yet a universally accepted design
that is widely used in practice. For a novel design to be frequently utilized in practice,
it not only needs to demonstrate desirable statistical properties, but also needs to be
easily understood by clinical investigators without backgrounds in statistics. CRM
was the first model-based design and it finally begin to be accepted by the medical
community. The method proposed by Wages and Tait [44] is essentially a design
using multiple CRM-like models to account for different shapes of the dose-efficacy
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curve. Therefore, it has the potential to be accepted by the medical community
since the rationale behind this design can be easily understood by people who are
familiar with CRM. Implementations of this design and its variations demonstrated
the potentials [50,51].
According to the method proposed by Wages and Tait [44], dose-toxicity and
dose-efficacy relationship are modeled in parallel. Dose-toxicity is modeled using the
traditional CRM from which a dose range with acceptable toxicity can be obtained.
In order to account for non-monotonic dose-efficacy relationships, multiple working
efficacy models are constructed based on a class of efficacy skeletons. Each of the
working efficacy model is constructed in a way that is similar to the CRM. The best-
fit working model is selected based on posterior model probabilities. The efficacy
probabilities can be estimated from the selected working model and next doses are
assigned based on the estimated efficacy probabilities. This method has demonstrated
desirable operating characteristics through simulations.
However, there are a few potential improvements that can be incorporated into the
original Wages and Tait design. First, the original Wages and Tait design constructs
multiple CRM-like models to account for different shapes of the dose-efficacy curve,
and uses a model selection criteria to choose a working efficacy model based on how
well each model fits the observed data. When sample size is small, there is not
enough data to conduct model selection. The original design proposed to randomize
an arbitrary number of patients based on the current best-fit model. This is referred
to as the adaptive randomization (AR) stage. We believe the AR stage could be
improved because the number of patients to be randomized is arbitrary and the
randomization probabilities are calculated from a working model that is selected
based on small sample size. Second, as discussed in the original article, this design
in its current form is most appropriate when both toxicity and efficacy endpoints
can be observed in a similar time-frame. In practice, there is sometimes a delay in
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the observation of endpoints, especially for efficacy. A TITE extension may be an
effective solution to delayed outcomes. Third, in order for a method to be understood
by other researchers and adopted in practice, there must be readily available software
for simulations and applications.
In this dissertation, our overarching goal is to evaluate potential improvements and
extensions to the seamless Phase I/II design proposed by Wages and Tait. In Chapter
2, we propose a redesign of the adaptive randomization stage used by the original
design [44] and use simulations to show improvements. In Chapter 3, we extend the
Wages and Tait design from binary endpoints to TITE endpoints. Simulations show
that this extension may substantially reduce the total trial duration while maintaining
approximately the same accuracy in selecting the OBD. In order to facilitate future
research and promote practical application, we build and introduce an R package in
Chapter 4 for the original Wages and Tait design as well as the modifications and
extensions. Finally, in Chapter 5, we discuss the results and possible future directions
of research.
Copyright c© Donglin Yan, 2018.
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Chapter 2 Improved Adaptive Randomization Strategies for a Seamless
Phase I/II Dose-Finding Design
2.1 Abstract
In this chapter, we propose and evaluate three alternative randomization strategies
to the adaptive randomization (AR) stage used in a seamless Phase I/II dose-finding
design. The original design was proposed by Wages and Tait [44] for trials of molec-
ularly targeted agents in cancer treatments, where dose-efficacy assumptions are not
always monotonically increasing. Our goal is to improve the design’s overall per-
formance regarding the estimation of optimal dose as well as patients allocation to
effective treatments. The proposed methods calculate randomization probabilities
based on the likelihood of every candidate model as opposed to the original design
which selects the best model and then randomizes doses based on estimations from
the selected model. Unlike the original method, our proposed adaption does not re-
quire an arbitrarily specified sample size for the AR stage. Simulations are used to
compare the proposed strategies and a final strategy is recommended. Under most
scenarios, our recommended method allocates more patients to the optimal dose while
improving accuracy in selecting the final optimal dose without increasing the overall
risk of toxicity.
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2.2 Introduction
Background
Historically, phase I trial designs have arisen from the development of chemothera-
pies starting in the 1940s [7]. A common objective of phase I trials in oncology is
to find the maximum tolerated dose (MTD) beyond which the consequence of toxi-
city outweighs any potential benefits. For chemotherapies, the MTD happens to be
the most promising dose for therapeutic benefits, because both odds of observing
toxicity and efficacy responses increase with dose levels. This traditional approach
aims to estimate the MTD of an agent, with subsequent phase II studies to evaluate
efficacy at the estimated MTD. Currently, most trials in Phase I use algorithm-based
designs, such as 3+3 escalation design [9, 52], step-wise design or A+B design [53]
due to their simplicity and long history of implementation. Model-based designs such
as the Continual Reassessment Method (CRM) [15] have shown superior statistical
properties over algorithm-based designs [18], and the use of model-based designs in
practice is increasing [21, 22]. After its original proposal, the CRM design gained
popularity among biostatisticians and several CRM-related designs were proposed to
handle more complex situations [16].
In recent years, the development of cytostatic cancer treatments such as molec-
ularly targeted agents (MTAs) [54] have shifted this paradigm in oncology clinical
trials. For MTAs, it is not always appropriate to assume that higher doses tend to re-
sult in higher probability of observing desired effects. Once an MTA reaches a certain
concentration level, higher doses may not increase efficacy, and efficacy could possibly
decrease after exceeding an intermediate dose [27]. In addition, MTAs are often used
in combination with cytotoxic agents. Even though MTAs are considered safer than
traditional chemotherapies, severe adverse events were observed in practice and can
not be predicated before the trial [33,34]. Therefore, the primary goal of these Phase
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I trials is to select the optimal biological dose (OBD) which is determined not only by
toxicity but also efficacy. Examples of these joint outcomes include balancing toxicity
with minimum effective blood concentration level of the agent, percent target inhi-
bition of a biomarker, or minimum expression level of a molecular target (targeted
biologic response) [55].
Locating the OBD
There is a trend in cancer treatment development to seamlessly integrate Phase I
and Phase II in order to accelerate drug development process and reduce costs. For
novel cancer treatments like MTAs, it becomes necessary to combine the objectives
of conventional Phase I and II studies since the search for OBD requires toxicity and
efficacy to be considered jointly. Several Phase I/II designs have been proposed to
incorporate efficacy data into the early stage of drug development during the last
decade, including a bivariate CRM design to incorporate efficacy [38], an adaptive
Bayesian method for Phase I dose finding based on trade-offs between the probabilities
of treatment efficacy and toxicity [39], a method used toxicity and efficacy odds ratios
and accounted for the correlation between toxicity and efficacy [41], and a two-step
Phase I/II trial sequence that identifies MTD using traditional methods in Phase I
and then search for OBD around the MTD in the following Phase II trials [36] among
others. In 2015, Wages and Tait proposed a seamless Phase I/II design that accounts
for non-monotonic dose-efficacy relationships by fitting multiple efficacy models and
using posterior model probabilities to select the best-fit efficacy model [44]. This
design combines features of the CRM design and order restricted inferences [48].
This design sequentially updates safety and efficacy probabilities in order to allocate
patients to the best guess of OBD from the accrued patient data.
The original Wages and Tait method models dose-toxicity and dose-efficacy rela-
tionship in parallel. Dose-toxicity is modeled using the traditional CRM from which
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a dose range with acceptable toxicity can be obtained. In order to account for non-
monotonic dose-efficacy relationships, multiple working dose-efficacy models are con-
structed based on a class of CRM skeletons. The best-fit model is selected based on
posterior model probabilities and the best-fit model is used to estimate efficacy prob-
abilities and assign dose for the next patients. Early in the trial, the observed sample
size is too small to correctly select the best fit model, hence, the dose estimated from
the selected model can not be relied on entirely. Some doses within the estimated
acceptable toxicity range may have never been tested. Therefore, an AR stage is
introduced to give every dose a chance to be tested. It also prevents the method from
prematurely favoring a particular model. The original AR stage randomizes the first
nAR patients based on the probabilities of efficacy estimated from the selected dose-
efficacy model. After the first nAR patients, the trial enters a maximization stage,
in which the patients are allocated to the most efficacious dose estimated from the
selected model.
Motivation
In this chapter, we introduce a redesign to the adaptive randomization (AR) stage in
the original design. In order to better illustrate our proposed revision, we will briefly
describe the original design in the next section and then introduce our proposed
adaptive randomization strategies.
We believe that the AR stage could be improved for several reasons. First, in
the early stage of the trial, there are too few data to accurately select the best dose-
efficacy model, therefore, the estimated efficacy probabilities are also not accurate.
Second, it is likely that the original approach picks a different efficacy model with each
new iteration, which leads to dramatic changes in the dose assigning probabilities.
Third, the size of AR phase nAR is arbitrarily selected, and a clear optimization of
nAR has yet to be identified. We propose a new method that replace the AR stage of
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the original design by Wages and Tait with the aim of improving the designs overall
performance. The method proposed below have several advantages. First, it does not
require a best-fit model to be selected when sample size is small. Instead, we weight
the suggested best dose from each candidate model and gradually reduce the number
of candidate models based on the amount of data accumulated. Second, we do not
need to arbitrarily specify a sample size nAR for the AR stage. Also, it simplifies the
design by merging several stages into one seamless process.
2.3 The original Wages and Tait dose-finding design
Consider a trial aimed at selecting the OBD of a new agent from a set of I pre-defined
dose levels D = {d1, d2, . . . , dI}. Toxicity and efficacy are observed through binary
endpoints Yj and Zj, where j = 1, 2, 3, . . . , N is the index of participating patient
ordered by sequence of enrollment.
Yj =

0, if not DLT
1, if DLT
, and Zj =

0, if no efficacy response
1, if observe efficacy response
.
The dose level to be administered on the jth subject is denoted by Xj ∈ D. After
observing the responses from the first n subjects, the toxicity and efficacy data can
be given in form of Ωn = {(x1, y1, z1), (x2, y2, z2), . . . , (xn, yn, zn)}
The probability of observing a DLT and efficacy response at each dose level is
denoted by piY (di) and piZ(di), respectively. We assume toxicity monotonically in-
creases with dose level, and an acceptable safe dose range A = {di|piY (di) < ξ} can
be obtained by the traditional CRM, where ξ is the maximum tolerated DLT rate.
Conventionally, the threshold value ξ is set to be 33%. OBD is defined as the dose
with the highest efficacy within the range that still assures safety
OBD = arg max
di∈A
{piE(di)}.
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Since the shape of the dose-efficacy curve is unknown, a class of L = 2 × I − 1
working models can be constructed (2I models have shapes that plateau or peak at
each dose level minus one duplicate), according to the original design by Wages and
Tait [44].
Let Q denotes a class of skeletons:
Q =

q1
q2
...
qL

=

q11 q12 q13 . . . q1I
q21 q22 q23 . . . q2I
. . .
qL1 qL2 qL3 . . . qLI

(2.1)
Each row q` ∈ Q is a set of skeletons, denoting a unique shape of the does-efficacy
curves. Elements in of the matrix, q`i ∈ Q, are constants that represents our initial
guesses of the probability of efficacy at dose level i, under the `th working model. For
example, if there are three dose levels, we can construct Q as a 5 by 3 matrix:
Q =

0.3 0.4 0.5
0.4 0.5 0.4
0.5 0.4 0.3
0.4 0.5 0.5
0.5 0.5 0.5

Using the `th row in Q and the empirical function, the `th efficacy model can be
expressed as
piE(di, `) = Pr(zj = 1|di, `) ≈ G`(xj; β`) = qexp(β`)`i , (2.2)
where pˆiE(di, `) is the estimated probability of observing a efficacy response on a pa-
tient tested at dose level di. Based on the observed efficacy data in Ωn, the likelihood
function can be expressed as
L`(β`|Ωn) =
n∏
j=1
{G`(xj,`)}zj{1−G`(xj, β`)}1−zj . (2.3)
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The posterior density of β` is
P`(β`|Ωn) = L`(β`|Ωn)h(β`)∫
β`
L`(β`|Ωn)h(β`)dβ` , (2.4)
where h(β`) is the prior distribution of the model parameter β`.
In addition, the posterior model probabilities given the observed data can be
established as
w(`|Ωn) = τ`
∫ L`(β`|Ωn)h(β`)dβ`
L∑`
=1
τ`
∫ L`(β`|Ωn)h(β`)dβ` , (2.5)
where τ` is the prior probability that the working model built on skeleton q` is the
best model to describe the dose-response relationship. For the rest of this chapter,
we set τ` = 1/L, but τ` can be adjusted to incorporate any existing knowledge of
the dose-efficacy relationship if available. Each time a new patient enters the trial, a
single model `∗ with the largest w(`|Ωn) is selected, so that
`∗ = arg max{w(`|Ωn)},
from which the probability of efficacy response piE(di, `
∗) is estimated.
Since w(`|Ωn) is obtained from small samples, especially in early stage of the
trial, we do not rely entirely on the w(`|Ωn) in selecting the best fit model. The
original design would randomize an arbitrary number of patients, nAR, based on the
estimated efficacy probability pˆiE(di, `
∗) if the estimated risk of toxicity is acceptable.
The original randomization probabilities are calculated as
Ri =
pˆiE(di, `
∗)∑
di∈A pˆiE(di, `
∗)
(2.6)
In the next section, we propose to randomize patients using w(`|Ωn) to weight the
implied best dose from each candidate model.
2.4 New adaptive randomization strategies
For ` = 1, 2, . . . , L, q` ∈ Q denotes the dose-efficacy skeleton over doses 1, 2, . . . , I. If
a model was built using skeleton q`, then the dose level recommended by this model
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can be expressed as S(`), that is
S(`) = min{arg max
i
(pˆiE(di ∈ A, `))}. (2.7)
The dose at level S(`) is expected to have the maximum chance of generating efficacy
response if the shape of dose-efficacy model ` is similar to the true dose-efficacy
relationship. The weight w(`|Ωn) indicates the probability that the model built on
skeleton qth` being the most consistent with the observed efficacy data. Therefore, we
propose the following strategies to randomize the enrolled patient with probability
R∗i .
Strategy 1: We propose to randomize the first nAR enrolled patients to the i
th
dose level with probability R∗i calculated as
R∗i =
2I−1∑
`=1
w(`|Ωn)I(di = S(`)), (2.8)
where I(·) is an indicator function. Equation (2.8) considers the recommended dose
from every candidate model and weights each recommendation by w(`|Ωn), whereas
the original design only considers the selected best-fit model. Similar to the original
design, nAR is arbitrarily selected and typically ranges from one third to one half of
the total sample size [44].
Strategy 2: A potential flaw of strategy 1 is that some of the candidate skeletons
and models are based on skeletons that have very different shapes than the true dose-
efficacy curve. Therefore, in strategy 2, we only consider a subset of candidate models
based on the posterior model probability w(`|Ωn). By definition,
∑L
`=1w(`|Ωn) = 1.
As more data are observed, models that better represent the true does-efficacy are
expected to have w(`|Ωn) > 1/L, indicating the data support some models while
contradicting the others. Therefore, we only consider models with w(`|Ωn) > 1/L
and calculate randomization probabilities by
R∗i =
R∗∗i
I∑
i=1
R∗∗i
, where R∗∗i =
2I−1∑
`=1
w(`|Ωn)I(di = S(`) and w(`|Ωn) ≥ 1/L). (2.9)
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Models with w(`|Ωn) < 1/L are temporarily excluded from the calculation of ran-
domization probabilities, but all models will be reevaluated when additional data are
observed. As n increases, we expect fewer models with w(`|Ωn) > 1/L. When n is
sufficiently large, there is one and only one best-fit model satisfying w(`|Ωn) > 1/L.
This strategy adaptively excludes less fit models and does not need nAR to be spec-
ified. When maximum sample size is reached and there are more than one models
satisfying w(`|Ωn) > 1/L, a best fit model `∗ = arg max`{w(`|Ωn)} can be selected
as the final dose-efficacy model, and the final dose selection is
S(`∗) = min{arg max
i
(pˆiE(di, `
∗)),max (A)} (2.10)
Strategy 3: In this strategy, we reduce the number of models being considered
based on the observed sample size.
R∗i =
R∗∗i
I∑
i=1
R∗∗i
, where R∗∗i =
2I−1∑
`=1
w(`|Ωn)I(di = S(`) and w(`|Ωn) ≥ w(L−L′+1)).
(2.11)
where I(·) is an indicator function, and w(1) ≤ w(2) ≤ · · · ≤ w(L) denote the ordered
posterior model probability w(`|Ωn). Equation (2.11) considers the recommended
dose from L′ best-fit models and weights the recommendations of each model by
w(`|Ωn). When the suggested dose is outside the safety dose range, the highest dose
in A will be used to ensure safety.
The number of models L′ to be considered for patient randomization is gradually
reduced from L to 1 based on the observed sample size n in relative to the planned
maximum sample size N .
L′ =
⌈(
N − n
N
)δ
L
⌉
, (2.12)
where δ is a constant referred to as the drop rate parameter. When δ = 1, one
candidate model is excluded from calculating the randomization probability for each
additional N/L patients. When 0 < δ < 1, models are dropped at a slower rate
23
Figure 2.1: An illustration of model selection process using a simulated trial of 30
patients. Drop rate δ = 2. A solid dot indicates the corresponding candidate model
is included in dose-assignment.
when sample size is small and faster when sample size is large, vice versa for when
δ > 1. When L′ = 1, only the best fit model will be considered and the next enrolled
patients will be randomized to the best dose recommended by the selected model
with 100% probability. We illustrate how candidate models are eliminated using a
simulated trial in Figure 2.1. Simulation studies are conducted to find appropriate
values of δ.
2.5 Trial conduct
Dose-finding algorithm
Starting the Trial: There are several options to assign dose for the first patient.
One may choose to start at the lowest dose level and use a simple escalation design
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until the occurrence of DLT. Another option is to determine the acceptable range A
from toxicity skeletons and calculate R∗i with w(`|Ωn=0) = 1/L. For the rest of this
chapter, we choose to start from the lowest dose under all circumstances.
Conducting the Trial: The trial conduct process varies slightly based on which
randomization strategy is adopted. When strategy 1 is used, the first nAR patients
are randomized based on equation (2.8). This stage is referred to as the AR stage.
The AR stage is followed by a maximization stage in which all patients are allocated
to the estimated best dose from a selected efficacy model.
When strategy 2 or strategy 3 is used, the AR stage and maximization stage can
be combined into one stage. Throughout the trial, all patients will be randomized
based on equation (2.9) or (2.11). It also ensures that all patients are only randomized
within the estimated safe range A. In early stage of the trial, patients are randomized
to a wide range of dose levels. However, the range of randomization is expected to
be narrowed down as data accumulates.
Ending the Trial: The trial ends when a pre-defined maximum sample size N is
reached. We can also terminate the trial early for safety when the acceptable range A
is empty or for futility when the upper bound of an exact binomial confidence interval
for efficacy is smaller than the standard treatment response rate at each dose level in
the acceptable range. Since the number of observations on each dose level is small,
conditions for early stopping rules are rarely met unless the true toxicity or efficacy
is extremely different than initially expected. Early termination rules are included to
avoid exposing patients to overly toxic or ineffective treatments.
Illustration
As an example, we describe a hypothetical Phase I/II dose-finding trial of the novel
antiangiogenic peptide ATN-161. We choose to use this agent as an example be-
cause inverse U-shaped dose-response curve was observed in preclinical studies [56].
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The possibility of non-monotonic dose-efficacy curve must be considered in designing
human trials. ATN-161 is a fiveamino acid peptide that binds to several integrins,
including α5β1 and αvβ3, that play a role in angiogenesis and tumor progression [57].
It has been shown to inhibit tumor growth and metastasis and extend survival in
multiple animal tumor models either when given as a single agent or when combined
with chemotherapy [58,59].
Suppose a phase I/II study of ATN-161 is conducted to select the OBD from a set
of I = 4 dose levels, and the total sample size is N = 30. We assume monotonic dose-
toxicity with toxicity skeleton set to be p = (0.1, 0.15, 0.2, 0.3). Since dose-efficacy
could potentially be inverse U-shaped or plateau shaped, we construct a class of 7
working efficacy models Q = (Q1,Q2)
T according to equation (4.1), with Q1 and Q2
respectively denoting peak and plateau shaped efficacy skeletons.
Q1 =

0.4 0.5 0.6 0.7
0.5 0.6 0.7 0.6
0.6 0.7 0.6 0.5
0.7 0.6 0.5 0.4

, and Q2 =

0.5 0.6 0.7 0.7
0.6 0.7 0.7 0.7
0.7 0.7 0.7 0.7
 .
The trial is conducted using the algorithm described above, and suppose we observe
the data summarized in Table 2.1 from the first 6 patients. The dose level for the
next enrolled patient can be determined as following.
Table 2.1: Hypothetical data for demonstration
Dose Level 1 2 3 4
Number of Patients 1 1 2 2
Number of DLT Response 0 0 0 1
Number of Efficacy Response 0 0 1 1
Based on a standard CRM model, we estimate the probability of DLT is below
33% at dose level 4, so A = {d1, d2, d3, d4}. Using equation (2.5), we calculate w(`|Ω6)
for each candidate model and display the results in Table 2.2. The original design
will select model ` = 1 as the current best fit efficacy model and randomize the next
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patient solely based on efficacy probabilities estimated from this model. According
to our proposed methods, we do not select the best fit model. Instead, we weight a
subset of all candidate models by w(`|Ω6).
Table 2.2: Numerical illustration of posterior model probabilities w(`|Dj) calculated
using equation (2.5). Data source: Table 2.1.
k 1 2 3 4 5 6 7
w(`|Ω6) 0.229 0.172 0.090 0.065 0.196 0.137 0.112
Dose level 4 is the suggested OBD by model ` = 1; dose level 3 is suggested by
model ` = 2 and 5; dose level 2 is suggested by model ` = 3 and 6; and dose level 1
is suggested by model ` = 4 and 7. We weight the suggested OBD of each candidate
model, and gradually reduce the number of models to be considered. Under strategy
1, all candidate models will be weighted. Under strategy 2, we only consider models
with w(`|Ω6) > 1/7, that is, models ` = 3, 4, 6, 7 will be excluded from calculating
randomization probabilities. The number of models to be considered under strategy
3 depends on the drop rate parameter δ, the observed sample size n, and total sample
size N . When the total sample size is N = 30 and the observed sample size is n = 6,
we will consider the top five best fit models when δ = 2, or the top four models when
δ = 3. For example, the probability of the next patient being randomized to the
lowest dose d1 is 0 when δ = 3, since model ` = 4 and ` = 7 are excluded at this
point. Randomization probabilities for each dose using each strategy are summarized
in Table 2.3.
Table 2.3: Numerical illustration of dose-assigning probabilities calculated by the
Original Wages and Tait method, and by the proposed method with δ = 2 and δ = 3.
.
Dose Level 1 2 3 4
Original Design 0.139 0.206 0.284 0.372
Strategy 1 0.176 0.227 0.368 0.229
Strategy 2 0 0 0.618 0.382
Strategy 3, δ = 2 0.1323 0.162 0.435 0.271
Strategy 3, δ = 3 0.000 0.187 0.501 0.312
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2.6 Simulation studies
We conduct two sets of simulation studies: the tuning study and the operative char-
acteristics study. In the tuning study, we evaluate the proposed method by varying
the drop rate parameter δ, and decide on the most appropriate value. In the second
set of simulations, we compare the proposed method to the original Wages and Tait
design.
Simulation settings
Sixteen combinations of true dose-toxicity and dose-efficacy relationships are assumed
in order to evaluate the performance of each design, which are summarized in Fig-
ure 2.2. Toxicity scenarios are denoted by T1 through T4 and efficacy scenarios are
denoted by E1 through E4. E1-E4 are scenarios where the true dose-efficacy is in-
creasing, plateaued, constant, or peaked. T1-T4 represent different toxicity profiles
where the true MTD is at various dose levels. Scenarios with E1-E3 and T1-T4 were
also used in simulation in the original Wages and Tait paper. We choose to use the
exact same scenarios so that the results are directly comparable. This also validates
our programs that utilize the original design. We include scenario E4 to assess the
performance of each design when efficacy decreases after the optimal dose level.
Under each scenario, we simulate 1000 trials with each trial selecting a recom-
mended dose from a set of I = 6 candidate doses. Using the definition used by the
original study, a best dose is defined as the level that has maximum chance of effi-
cacy while assuring safety, and a good dose is the level with 25% or higher chance
of efficacy while assuring safety. We define safety as 33% or lower DLT rate. The
performance of a design is evaluated by the probability of selecting good/best dose
and the average number of patients treated at good/best dose.
For both methods, toxicity is modeled by traditional CRM using a power model
with skeleton p = {0.01, 0.08, 0.15, 0.22, 0.29, 0.36}. We justify the use of a single
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Figure 2.2: True dose-toxicity and dose-efficacy curves in the simulation study. T1-T4
represent different toxicity levels. E1-E4 represent monotonic, plateaued, constant,
and peaked dose-efficacy scenarios, respectively.
skeleton for all scenarios by robustness of the CRM method [60]. Efficacy is modeled
with skeletons constructed using equation (4.1). The numerical values of efficacy
skeletons are presented in Table 2.4. The same skeletons are used in all simulation
scenarios for both methods to minimize potential bias in simulation studies.
Tuning δ for Strategy 3
Recall that in equation (2.12), the value of L′ is controlled by the drop rate parameter
δ. In this set of simulations, we compare the proposed design with difference choices
of δ ranging from 0.5 to 4. In additional to different dose-toxicity and dose-efficacy
scenarios, we also conduct simulations with different total sample size N = 48, N =
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Table 2.4: Skeletons for efficacy models used in all simulation scenarios. There are
6 candidate dose levels, and 11 efficacy models are constructed to account for mono-
tonic, plateaued or peaked dose-efficacy curves.
` Efficacy Model Skeletons
1 q1 = (0.60, 0.50, 0.40, 0.30, 0.20, 0.10)
2 q2 = (0.50, 0.60, 0.50, 0.40, 0.30, 0.20)
3 q3 = (0.40, 0.50, 0.60, 0.50, 0.40, 0.30)
4 q4 = (0.30, 0.40, 0.50, 0.60, 0.50, 0.40)
5 q5 = (0.20, 0.30, 0.40, 0.50, 0.60, 0.50)
6 q6 = (0.10, 0.20, 0.30, 0.40, 0.50, 0.60)
7 q7 = (0.20, 0.30, 0.40, 0.50, 0.60, 0.60)
8 q8 = (0.30, 0.40, 0.50, 0.60, 0.60, 0.60)
9 q9 = (0.40, 0.50, 0.60, 0.60, 0.60, 0.60)
10 q10 = (0.50, 0.60, 0.60, 0.60, 0.60, 0.60)
11 q11 = (0.60, 0.60, 0.60, 0.60, 0.60, 0.60)
64 and N = 80. We only present the results with N = 64, as similar conclusions can
be drawn for different values of N .
We summarize the results in Figure 2.3 which consists of four plots, A, B, C, and
D, each representing a different criteria of performance. Full simulation results are
provided in Appendix. Figure 2.3-A and 2.3-B respectively assess each value of δ by
the chance of selecting best dose or a good dose. In Figure 2.3-C and 2.3-D, different
values of δ are evaluated by the average number of patients allocated to best/good
dose levels. Relative performance is calculated as the difference between a particular
value of δ and the average performance of all five values of δs.
Figure 2.3-A and 2.3-B show that δ = 2 and δ = 3 perform better than the other
values in most scenarios with E2 and E4. All methods perform similarly in scenarios
with E3. Starting from δ = 4, we begin to see decreases in accuracy of selecting the
right dose in scenario E1T4. δ = 0.5 and δ = 1 perform exceptionally well when
dose-efficacy is monotonically increasing and toxicity is constant at a very low level.
However, their performance is relatively inferior in scenarios with E2. Figure 2.3-C
and 2.3-D show that δ = 2, and δ = 3 allocate significantly more patients to either
the best dose or a good dose throughout the trial under all twelve scenarios.
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In conclusion, we find δ = 2 and δ = 3 have better performance under most
scenarios except for R1T4. In E1T4, the performance of δ = 2 and δ = 3 are slightly
inferior than δ ≤ 1. Therefore, we recommend δ = 2 or δ = 3 when the total sample
size is between 48 and 80 which is a commonly used sample size in phase I/II studies.
With 2 ≤ δ ≤ 3, it only takes a few of observations to exclude a model in the early
stage and most patients are randomized based on several similar models.
Figure 2.3: Plots A, B, C, D respectively evaluate different values of δ in strategy 3 by
the probability of selecting the best dose, probability of selecting a good dose, average
number of patients treated at the best dose and average number of patients treated
at a good dose. Relative performance is calculated as the difference in performance
between a particular value of δ and the overall average performance of all δs. Higher
number indicates better than performance.
31
Operating characteristics
Another set of simulations compare the proposed randomization strategies to the
original Wages and Tait design. The original Wages and Tait design chose to use
nAR = 16 as the sample size for the AR stage. We also include nAR = 32 and nAR =
48 for comparison. We denote the original designs by ‘WT’ followed by nAR, that is,
‘WT-16’,‘WT-32’, and ‘WT-48’. Strategy 1 is simulated using nAR = 16, 32, and 48,
which are denoted by ‘S1-16’, ‘S1-32’, and ‘S1-48’, respectively. Strategies 2 and 3
do not require nAR to be specified. Strategy 3 uses δ = 2 or δ = 3 as suggested by
the previous set of simulations, and we denote them by ‘S3-D2’ and ‘S3-D3’. The
total sample size for all designs is set to N = 64. Toxicity and efficacy outcomes are
simulated as correlated variables with correlation parameter equals to 4.6 in order to
match with settings of the original study. We also conducted simulations using other
correlation parameter values, including independent toxicity and efficacy outcomes.
For the sake of simplicity, we omit those simulations since the results are very similar.
Similar to the previous set of simulations, we report the results in Figure 2.4-A
through Figure 2.4-D, and provide the full results in the Appendix. Strategy 1 with
various nAR occasionally performs better than the original method by a very small
margin and sometimes performs worse. Hence, there is not evidence to recommend
strategy 1. Strategies 2 and 3 outperform the original method by a higher probability
in selecting best/good dose and a larger number of patients treated at the best/good
dose in all but one scenario. In scenario E1T4, the original design with nAR = 48
has better accuracy in selecting the best dose and allocates more patients to the best
dose when nAR = 16. However, we argue that the performance of strategies 2 and 3
is still acceptable. Our methods tend to select and allocate patients to be the best
dose as well as the next lower dose. When the criteria is selecting/allocating to a
good dose, Figure 2.4-B and 2.4-D show that the performance of the proposed design
is very close to that of the original in E1T4.
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Relative to strategy 2, strategy 3 is marginally more accurate in selecting the
best/good dose, and both strategies have similar performance regarding treating
patients at the best/good dose. Therefore, we recommend using strategy 3 with
δ = 2 or 3 as the method of randomization.
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Figure 2.4: Plots A, B, C, D respectively evaluate different values of δ by the probability of selecting the best dose, probability
of selecting a good dose, average number of patients treated at the best dose and average number of patients treated at a good
dose. Relative performance is calculated as the difference in performance between a particular method and the overall average
of all methods. Higher number indicates better than performance.
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2.7 Discussion
In this chapter, we introduced and evaluated three alternative randomization strate-
gies as modifications to a design proposed by Wages and Tait (2015). The original
design requires a selection of the best-fit model even when the observed sample size
is very small. In our final recommended randomization strategy, we eliminate the
need to select the best model by evaluating and weighting every candidate model and
gradually excluding unfit models as data accumulate. The revised design not only
demonstrated better accuracy in selecting the OBD, but also allocated more patients
to better treatment regimens. In addition, the original design includes two different
stages while the proposed method simplifies it into one seamless process.
A limitation of the proposed design is the assumption that toxicity and efficacy
data can be observed shortly after treatment. In real clinical practice, delayed re-
sponses are very common,as toxicity and may not be observed at the same time.
Since time to event is not considered in this design, we can only enroll the next pa-
tient when both toxicity and efficacy outcomes are observed to update the models.
Future studies can be conducted to include treatment cycles or length of treatment
in order to shorten the total trial duration and make the design more applicable in
real clinical settings with delayed responses.
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Chapter 3 Bivariate Generalization of the Time-to-Event Continual
Reassessment Method
3.1 Abstract
This chapter considers the problem of designing Phase I-II clinical trials with delayed
outcomes. This design is motivated by is a Phase I-II study evaluating optimal dosing
of all-trans retinoic acid (ATRA) in combination with a fixed dose of daratumumab
in the treatment of relapsed or refractory multiple myeloma. The toxicity endpoint is
observed in one cycle of therapy (i.e., 4 weeks) while the efficacy endpoint is assessed
after 8 weeks of treatment. The difference in endpoint observation windows causes
logistical challenges in conducting the trial, since it is not practical to wait until both
outcomes for each participant have been observed before sequentially assigning the
dose of a newly eligible participant. In order to avoid delays in treatment for newly
enrolled patients and to accelerate trial progress, we generalize the time-to-event con-
tinual reassessment method (TITE-CRM) to bivariate outcomes. Simulation studies
are conducted to evaluate the proposed method, and we found that the proposed
design substantially reduces the total trial duration with promising operating char-
acteristics. However, the number of patients treated at the correct dose is affected
by the rate of enrollment.
36
3.2 Introduction
Background
Historically, the primary objective of Phase I clinical trials is to identify the maximum
tolerated dose (MTD) of the agent or agents being investigated. In a subsequent
Phase II trial, the agent is evaluated for efficacy, often at the recommended dose
(MTD). In oncology trials of chemotherapeutic agents, identification of the MTD
is usually determined by considering dose-limiting toxicity (DLT) information only,
with the assumption that the MTD is the highest dose that satisfies some safety
requirement, so that it provides the most promising outlook for efficacy. In gen-
eral, the design of Phase I trials is driven by the assumption of monotone increasing
dose-toxicity and dose-efficacy relationships. Numerous Phase I designs have been
proposed for identifying the MTD by studying the dose-limiting toxicity (DLT) in-
formation through the use of binary outcomes, including [52] [15] among many others.
By contrast, many biological agents are assumed safe overall and higher doses do
not necessarily produce greater efficacious response. However, we must still monitor
for the unexpected and account for safety. Conditional on safety, other endpoints may
be the main summary endpoint that is used to determine which dose to carry forward.
Examples include an early measure of efficacy (i.e. clinical response); pharmacoki-
netic/pharmacodynamics; biological targets (i.e. immune response). Dose-efficacy
relationships may exhibit non-monotone increasing patterns, such as increasing at
low doses and plateauing at higher levels, or peaking at an intermediate dose. For ex-
ample molecules with anti-angiogenic activity often appear to exhibit hormesis, i.e.,
bell-shaped dose-response curves [27]. A review of 24 Phase I targeted therapy trials
show that patient receiving lower doses do not fare worse [61]. A lower dose than
the MTD may exhibit as much activity as higher doses, and beyond this dose we are
merely adding toxicity. If the dose-efficacy relationship is monotone increasing, the
37
MTD is the lowest safe dose providing the highest efficacy. In this case, we would want
a dose-finding method to be able identify the MTD. However, if the dose-efficacy re-
lationship plateaus at a dose lower than the MTD, we would want to recommend this
lower dose. The goal of the trial shifts to identifying the optimal biologic dose (OBD),
which is defined as the lowest dose with acceptable toxicity that maximizes efficacious
response. In recent years, there have been several new methods proposed for locating
the OBD in Phase I-II trials of biological agents, including [42], [38], [39], [44], among
many others. A comprehensive overview of Bayesian designs for Phase I-II clinical
trials is provided by Yuan, Nguyen, and Thall [49].
The design by Wages and Tait [44] is most appropriate when both binary toxicity
and binary efficacy endpoints can be observed in a reasonably similar and short time-
frame. A drawback of that method is that it requires efficacy and toxicity responses
to be fully observed before it can be used to assign a dose to the next enrolled patient,
Yin [37] and Yuan [43] note that in some practical situations, this may not be possible
due to the fact that efficacy may occur much later than toxicity. For example, in a
targeted agent or immuno-therapy trial, toxicity outcomes can often be observed in
a relatively timely manner after treatment administration but efficacy is observed in
a relatively longer time-frame. If this delay is expected, then the method outlined in
Wages and Tait [44] is not optimal in its existing form because the trial would have
to either pause before each patient is enrolled in order to fully observe the efficacy
responses or to assign doses base on less efficacy data than toxicity data. If the delay
is particularly long, then it will cause the duration of the trial to be much too long
and wastes resources [43]. However, a modified approach can be applied to account
for the delayed efficacy response. In this chapter, we outline a method for identifying
the OBD using partial follow-up information that combines features of the continual
reassessment method (CRM) [15], partial order CRM [48], and the time-to-event
(TITE) CRM [23]. The rest of this chapter is organized as follows.
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In the following sections, we first outline the statistical models and inference
used in the proposed design, and describe the dose-finding algorithm. Then, we
provide numerical results illustrating the operating characteristics of the design. We
also provide a case study to demonstrate the design. Finally, we conclude with a
discussion.
Locating the OBD
Consider a trial aimed at selecting the OBD of a new agent from a set of I pre-
defined dose levels D = {d1, d2, . . . , dI}. Toxicity and efficacy are observed through
time dependent binary endpoints Yj,n and Zj,n, where j = 1, 2, 3, . . . , N is the index of
participating patients ordered by sequence of enrollment, and n denotes the number
of patients currently being tested. Denote the toxicity probability at each dose level
by piY (di), and the efficacy probability at each dose level by piE(di). Based on the
pre-specified target toxicity upper bound ξ, we want to exclude overly toxic doses,
defining a set of acceptable (safe) doses as A = {di|piY (di) < ξ}. For the rest of this
chapter, we set ξ = 33%. The primary objective of the study is to identify the OBD,
defined the dose that maximizes efficacy, conditional on safety so that:
OBD = arg max
di∈A
{piE(di)}. (3.1)
The goal, both within and at the conclusion of the study, is to locate the OBD while
some patients are still under observation for toxicity and efficacy responses.
A motivating example
This work is motivated by a Phase I-II clinical trial studying the optimal dosing of all-
trans retinoic acid (ATRA) [62] in combination with a fixed dose of daratumumab [63]
in the treatment of relapsed or refractory multiple myeloma. The trial was designed to
find the OBD from among three dose levels of ATRA {15, 30, 45 mg/m2} and a fixed
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dose of daratumumab 16 mg/kg. The decision endpoints are dose-limiting toxicities
(DLTs), based on protocol-specific adverse event definitions, in one cycle (i.e., 28
days) of therapy, and early measures of efficacy, defined by at least a 25% reduction
in M-protein in serum, 50% reduction in Bence-Jones proteinuria, or 25% reduction in
plasmacytomas in patients with non-secretory disease after 8 weeks of treatment. To
address the problem of delayed efficacy, we propose a time-to-event (TITE) extension
to the method of Wages and Tait, which was only able to handle bivariate binary
outcomes that were observable in a reasonably similar time frame. Other Phase I-II
methods that are able to handle delayed outcomes include [43]; [64]; and [45].
3.3 Proposed time to event extension
We propose a TITE extension to the Wages and Tait [44] method to incorporate the
use of partial follow-up information. Similar to the TITE CRM proposed by [23], the
general idea is to incorporate all available information including the length of time a
patient is on treatment into the model.
Let tj,n denotes the follow-up time for patient j by the time the (n+ 1)
th patient
is enrolled. The maximum follow-up time is denoted by T . Note that toxicity and
efficacy outcomes may have different maximum follow-up time. The observed toxicity
and efficacy response, Yj,n and Zj,n are dependent on tj,n. Note that the value of Yj,n
and Zj,n may change from 0 to 1 as n increases, indicating toxicity/efficacy effects
manifest after certain time point. For each patient, we assume there are unobservable
thresholds tTj and t
E
j , only beyond which a positive toxicity or efficacy response can
be observed.
Yj,n =

0 (no DLT ) when tj,n < t
T
j
1 (observe DLT ) when tj,n ≥ tTj
, Zj,n =

0 (no efficacy) when tj,n < t
E
j
1 (observe efficacy) when tj,n ≥ tEj
Dose level administered on the jth subject is denoted by Xj ∈ D. At the enrollment
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of the (n+ 1)th patient, data observed from the first nth patients can be expressed in
form of ΩTn = {(xj, yj,n, zj,n, tj,n)} for j = 1, 2, . . . , n.
Models and inference for toxicity
Toxicity is modeled using TITE-CRM as proposed by Cheung and Chappell [23]. We
only briefly describe the CRM and TITE-CRM here. The CRM is built on a given
set of constants, called the skeletons p = (p1, p2, p3, . . . , pI), with pi representing our
initial guesses of the toxicity risk at dose di. Toxicity is modeled by a parametric
function piY (di) = F (θ, di). F (·) must be monotone increasing given any pi. For
example, the power model F (θ, di) = p
exp(θ)
i , is a common choice.
When toxicity responses can be observed within a reasonable time-frame, the
toxicity outcome for each subject j is simplified into a binary endpoint Yj that is
independent of time. In the case of a power model, the likelihood function given
observed data Ωn is
L(θ|Ωn) =
n∏
j=1
{pexp(θ)xj }Yj{1− pexp(θ)xj }1−Yj .
θˆ can be estimated from the posterior distribution or by maximizing the likelihood
function. The probability of DLT at each dose level is estimated by pˆiY (di) = F (θˆ, di).
TITE-CRM is an extension of the CRM by considering a weighted dose response
model piY (di, w) = G(di, τ, θ) = τF (θ, di). The weight τ depends on the length of time
a subject has been treated. If a toxicity response is observed, then the observation is
given full weight τj = 1; otherwise, define weight for subject j as τj = tj,n/T . There
are other options for weight function, but for the purpose of this chapter, we choose to
use this linear weight function. Using weighted power model, the likelihood function
can be expressed as
Lw(θ|Ωn) =
n∏
j=1
{τj(tj,n, T ) · pexp(θ)xj }Yj,n{1− τj(tj,n, T ) · pexp(θ)xj }1−Yj,n .
Model estimation and dose assignment can be done similarly to the CRM.
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Models and inference for efficacy
As in original design by Wages and Tait [44], efficacy is modeled by constructing
multiple working models for efficacy and utilizes model selection to allow for the
uncertainty in the dose-response curve. Both unimodal and plateau skeletons for a
total of L = 2I − 1 models that are included in the set of possible models. For
example, if I = 6, then we can construct a set of 11 working models as specified in
equation (3.8). For a particular working skeleton `, ` = 1, 2, . . . , 2I − 1, there is a
model
piE(di) = Pr(Zj = 1|di) ≈ G`(di; β`) = qexp(β`)i` (3.2)
from a class of working does-efficacy models G`(di; β`). Uncertainty in dose-response
curve is taken into account through the posterior model probabilities of the efficacy
models.
Given ΩTn , the weighted likelihood for efficacy model ` at the enrollment of the
n = 1th patient can be expressed as
Lw` (β`|Ωn) =
n∏
j=1
{τj(tj,n, T ) · qexp(β`)`xj }Zj,n{1− τj(tj,n, T ) · q
exp(β`)
`xj
}1−Zj,n . (3.3)
where the weight function τE(tj,n, T ) denotes the weight given to the outcome ob-
served from the jth patient by the time n patients have received the treatment. T
is a constant denoting the observation window of the outcomes. τ(tj,n, T ) represents
the proportion of follow-up time completed. We choose to use the linear weighting
scheme, that is,
τ(tj,n, T ) =

arg min(tj,n/T, 1) if no response observed at tj,n
1 if response observed at tj,n
τ (tj,n, T ) = 1 when tj,n ≥ T , denoting patient j has completed efficacy observation.
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For the likelihood function of each candidate model `, we proceed by evaluating
the likelihood of the model with posterior model probability give by:
w(`|Ωn) =
p(`)
∫
β`
Lw` (β`|Ωn)h(β`)dβ`
L∑`
=1
p(`)
∫ Lw` (β`|Ωn)h(β`)dβ` , (3.4)
where p(`) is the prior model probabilities. One option is to set p(`) = 1/L for all `s so
that every model is equally likely at the beginning of the trial, or we may set p(`) = 0
for some models if the drug mechanism indicates that such dose-efficacy relationships
are not plausible. Each time a new patient enters the trial, all candidate models will
be evaluated by their likelihood of representing the true dose-efficacy relationship.
As proposed in the multidimensional CRM, we can choose model `∗ with the largest
posterior probability such that `∗ = arg max{w(`|Ωn)} and estimate the probabilities
of efficacy at each dose through
pˆiE(di, `
∗) = G`∗(di, βˆ`∗|Ωn),
where
βˆ`∗ =
∫
β`∗
βLw`∗(β`∗|Ωn)h(β`∗)dβ`∗∫
β`∗
Lw`∗(β`∗ |Ωn)h(β`∗)dβ`∗
.
In the original Wages and Tait method [44], patients will be assigned to the dose with
highest estimated efficacy probability. When sample size is very small, that is, when
n < nAR with nAR being a prespecified constant, patients will be randomized within
the safe range A based on the estimated efficacy probabilities. Randomization of the
first nAR patients is referred to as the adaptive randomization stage.
In Chapter 2, we showed that an alternative randomization strategy tends to per-
form better regarding the accuracy of optimal dose selection and patients allocation
to optimal doses. This alternative randomization strategy also eliminates the need of
specifying nAR. Therefore, for our proposed method, we choose to use the following
randomization strategy.
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The implied best dose from each candidate model can be given as
S(`) = min{arg max
i
(piE(di ∈ A, `))}. (3.5)
Therefore we can adaptively randomize patients based on the likelihood of each model
and its corresponding best dose S(`). The randomization probability is calculated as
R∗i =
R∗∗i
I∑
i=1
R∗∗i
, where R∗∗i =
2I−1∑
i
w(`|Ωn)I(di = S(`) and w(`|Ωn) ≥ w(L−L′+1)).
(3.6)
where I(.) is an indicator function. w(1) ≤ w(2) ≤ · · · ≤ w(L) denote the ordered
posterior model probability w(`|Ωn). L is the total number of candidate models
and L′ is the number of models being considered in the calculation of randomization
probabilities. Equation (3.6) considers the recommended dose from L′ best-fit models
and weights the recommendations of each model by w(`|Ωn). Initially, there are
L = 2I − 1 candidate models. Some models are mutually exclusive. Therefore,
instead of considering all candidate models, we reduce the number of models being
considered based on the observed sample size in relative to the total sample size N :
L′ =
⌈(
N − n
N
)δ
L
⌉
, (3.7)
where δ is a prespecified constant. As shown Chapter 2, we recommend to use δ = 2
or δ = 3 when total sample size is between 32 and 64. This allows the method to
drop candidate models with fewer observations in the beginning stage of the trial,
but more data are required to exclude a model towards the end.
Dose-finding algorithm
Starting the Trial: In order to get the trial underway, we will choose the efficacy
skeleton with the largest prior probability, p(`), among the orders being considered.
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If several, or all, of the models have the same maximum prior probability, then there
are several options to assign the dose for the first patient. One may choose to start at
the lowest dose level or the prior-estimated MTD. Another option is to determine the
acceptable range A from toxicity skeletons and the first patient will be randomized
with probability R∗i assuming w(`|Ωn=0) = 1/L. For the purpose of this study, we
choose to start from the lowest dose.
Conducting the Trial: After the first patient, we update the data and re-fit the
model each time another subject is enrolled into the study. Throughout the trial, all
patients will be randomized based on equation (3.6). Our method ensures that all
patients are only randomized within the estimated safe range A. In early stage of the
trial, patients are randomized to a wide range of dose levels. However, the range of
randomization is expected to converge to the optimal dose as data accumulates.
Ending the Trial: The trial ends normally when a pre-defined maximum sample
size N is reached. If the acceptable range A is empty during the trial, the study will
be closed for safety. We may also close the trial early for futility or efficacy based on
the exact binomial confidence interval for efficacy.
3.4 Simulation studies
Design specifications and model priors
In order to examine the operating characteristics of the proposed method, we conduct
an extensive simulation study. There are 6 candidate doses from which the best dose is
selected. We set the sample quota to be N = 60 and the maximum toxicity tolerance
to be ξ = 33%. Under each scenario, each method is simulated for 1000 iterations
and the average results are compared by the accuracy of OBD selection, number of
patients treated at the OBD and total trial duration.
We use the same priors for both of the methods. Toxicity prior skeleton is chosen
as (p1, p2, p3, p4, p5, p6) = (0.20, 0.30, 0.40, 0.50, 0.60). L = 11 possible efficacy models
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are constructed as:
Q =

q1
q2
q3
q4
q5
q6
q7
q8
q9
q10
q11

=

0.60, 0.50, 0.40, 0.30, 0.20, 0.10
0.50,0.60, 0.50, 0.40, 0.30, 0.20
0.40, 0.50,0.60, 0.50, 0.40, 0.30
0.30, 0.40, 0.50,0.60, 0.50, 0.40
0.20, 0.30, 0.40, 0.50,0.60, 0.50
0.10, 0.20, 0.30, 0.40, 0.50,0.60
0.20, 0.30, 0.40, 0.50,0.60,0.60
0.30, 0.40, 0.50,0.60,0.60,0.60
0.40, 0.50,0.60,0.60,0.60,0.60
0.50,0.60,0.60,0.60,0.60,0.60
0.60,0.60,0.60,0.60,0.60,0.60

. (3.8)
q1 through q6 represent scenarios where the dose-efficacy peaked at dose d1 through
d6, respectively; q7 through q11 are scenarios when dose-efficacy plateaus after the
optimal dose. We assume no existing knowledge about the candidate models and set
h(`) = 1
11
for ` = 1, 2, . . . , 11.
TITE distributions
A couple of assumptions can be made on the arrival times of the patients in a clinical
trial and the observation time of toxicity and efficacy responses. We assume the
arrival of patients follows a Poisson distribution, with mean µ = 0.25, 1 or 2 denoting
the expected number of patients per week.
The time to event of toxicity or efficacy response is assumed to follow either a
conditional uniform distribution or a Weibull distribution. For a conditional uni-
form distribution, the TITE would be randomly chosen from the interval (0, Ttox)
or (0, Teff ) when a patient experiences a toxicity or efficacy event. We assume all
toxicity and efficacy events will occur before Ttox and Teff , respectively. An alterna-
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tive assumption is the underlying TITE distribution follows a Weibull with a fixed
shape parameter of 4 as in Cheung [23]. We take the same approach with the scale
parameter, γ, as Cheung [23] and Braun [65] took and set it to make the cummulative
distribution function at T equals to the probability of a response of the current dose
level, that is,
F (x; γ) =
∫ T
0
4
γ
x3 exp−(x/γ)
4
dx = piE(di),
where T = Ttox for toxicity responses and T = Teff for efficacy responses. We assume
the maximum observation time for efficacy is Teff = 12 weeks and separately simulate
scenarios when toxicity can be observed in Ttox = 4 weeks and Ttox = 12 weeks.
Since we do not know the underlying distribution of the TITE variable, we simu-
late various truths for the TITE distribution. Note that ‘U’ denotes a conditionally
Uniform distribution of the TITE variable; ‘W’ denotes a Weibull distribution.
Dose response scenarios
The dose-response scenarios are presented in Table 3.1. In scenario S1-S6, dose-
toxicity is generally increasing but the overall toxicity rate is relatively low. The
best dose occurs at level 1 through level 6 respectively. Scenario S7 through S9
represents scenarios with high toxicity rate and the true MTD is dose 4. Dose-efficacy
in scenarios S7 through S9 is constant, increasing, and decreasing respectively.
Operating characteristics
Table 3.2 and Table 3.3 examine the operating characteristics of the proposed method
regarding its ability to correctly select the OBD as well as the number of patients
treated at the best dose. Table 3.2 summarizes results from simulations where toxicity
outcomes can be observed within 4 weeks of treatment while efficacy effect takes 12
weeks to be observed; results in Table 3.3 are simulated assuming both toxicity and
efficacy outcomes can be delayed up to 12 weeks.
47
Table 3.1: True probabilities of observing toxicity and efficacy responses at each dose
levels.
Dose level
Scenario 1 2 3 4 5 6
S1
Toxicity 0.02 0.03 0.05 0.06 0.07 0.07
Efficacy 0.40 0.25 0.20 0.15 0.10 0.05
S2
Toxicity 0.02 0.04 0.07 0.09 0.10 0.15
Efficacy 0.15 0.45 0.30 0.25 0.16 0.10
S3
Toxicity 0.01 0.02 0.03 0.04 0.05 0.06
Efficacy 0.10 0.15 0.35 0.18 0.12 0.07
S4
Toxicity 0.01 0.02 0.04 0.06 0.08 0.10
Efficacy 0.05 0.15 0.30 0.45 0.35 0.30
S5
Toxicity 0.01 0.02 0.03 0.05 0.06 0.07
Efficacy 0.15 0.25 0.33 0.47 0.60 0.40
S6
Toxicity 0.01 0.02 0.03 0.04 0.05 0.06
Efficacy 0.05 0.15 0.30 0.35 0.40 0.50
S7
Toxicity 0.05 0.10 0.16 0.30 0.40 0.50
Efficacy 0.30 0.30 0.30 0.30 0.30 0.30
S8
Toxicity 0.05 0.10 0.16 0.30 0.40 0.50
Efficacy 0.10 0.20 0.30 0.40 0.50 0.60
S9
Toxicity 0.05 0.10 0.16 0.30 0.40 0.50
Efficacy 0.50 0.40 0.30 0.20 0.10 0.05
Overall, the proposed method showed encouraging selection accuracy under var-
ious dose-response scenarios and different underlying simulation assumptions. The
chance of correctly selecting the OBD generally ranges from 50% to 70%, except for
scenario S6 and S7 under which the chance is only about 30%. The proposed method
showed robustness against varying TITE distribution as well as the rate at which
patients are enrolled. Whether the TITE follows a Weibull or conditional Uniform
distribution, the chance of selecting the OBD remains the same. Similarly, the rate
of patient arrival do not diminish the ability to select the OBD.
The distribution of patient allocation centers at the OBD with an average of 25
patients treated at the best dose. Note that even though the accuracy of dose se-
lection is not affected by patient arrival rate, the distribution of patient allocation
significantly depends on how fast patients are enrolled. The slower patients are en-
rolled, the more likely they are treated at the OBD, as more information become
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available for dose assignment.
We further analyze scenario S6 and scenario S7 as results from these two scenarios
are less desired than the others. Table 3.4 is a subset of the simulation results detailing
the dose selection and patient allocation distribution for scenario S6 and S7. In table
3.4, the patient enrollment follows a Poisson distribution with rate = 0.25. Toxicity
outcomes can be observed within 4 weeks. In scenario S6, both toxicity and efficacy
are monotonically increasing with OBD being the highest dose. The results indicate
that the proposed method is overly conservative and tends to select the highest 3
dose levels with similar probabilities. Patient allocation distribution centers at the
next highest dose.
In scenario S7, all dose levels have the same efficacy probabilities while MTD is
at the 4th dose. The exact OBD is the first dose but dose 1-4 are also acceptable.
Therefore, even though the probability of selecting OBD is only about 30%, most
of the time, the selected dose is still acceptable. Similarly, the vast majority of the
participating patients are treated at an efficacious dose level with less than 33% DLT
probability.
An advantage of the proposed method is that the design significantly shortens the
expected trial duration as dose assignment can be performed using partial informa-
tion from patients who are still under observation. The trial duration shortens to
approximately 5, 1.5 or 0.8 years when the rate of patient enrollment is respectively
0.25, 1, and 2 patients/week, as compared to 15 years if the next patient can only be
enrolled when all current patients have completed follow up.
3.5 Application to motivating example
Recall the motivating example that studies the optimal dosing of ATRA in combi-
nation with a fixed dose of daratumuman in the treatment of relapsed or refractory
multiple myeloma. The trial aims at selecting the optimal dose from three candidate
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Table 3.2: Simulation results: toxicity and efficacy outcomes are observed for 4/12
weeks, respectively. ‘U’ and ‘W’ respectively denotes a conditionally Uniform dis-
tribution and Weibull distribution of toxicity or efficacy TITE. The enrollment of
patients follow a Poisson process, with Rate=0.25, 1, or 2. The estimated probability
of selecting the OBD is summarized in column ‘Select’, and the average number of
patients treat at the OBD is under column ‘Treat’.
Tox Eff Rate Select Treat Tox Eff Rate Select Treat Tox Eff Rate Select Treat
Scenario 1 Scenario 2 Scenario 3
U U 0.25 67.6 28.8 U U 0.25 69.3 27.4 U U 0.25 69.3 26.9
U U 1 72.4 28.8 U U 1 67.9 24.3 U U 1 73.3 26.7
U U 2 75.2 26.9 U U 2 62.3 20.9 U U 2 70.6 23.7
U W 0.25 66 28.3 U W 0.25 66.9 26 U W 0.25 71.7 27.6
U W 1 72.6 26.6 U W 1 69.5 23.6 U W 1 71.3 24.6
U W 2 76.3 23.7 U W 2 66.1 18.5 U W 2 71.3 21
W U 0.25 67.9 28.9 W U 0.25 66.6 26.4 W U 0.25 71.6 28
W U 1 71.7 28.4 W U 1 66.4 23.9 W U 1 72 26.3
W U 2 73.6 26.6 W U 2 63.5 20.6 W U 2 69.6 23.4
W W 0.25 72 29.5 W W 0.25 67.3 25.8 W W 0.25 68.5 26.4
W W 1 73.4 26.8 W W 1 68.9 22.6 W W 1 75.1 25.7
W W 2 76.9 23.1 W W 2 66.4 18.9 W W 2 71.2 20.7
Scenario 4 Scenario 5 Scenario 6
U U 0.25 59.2 24 U U 0.25 59.7 24.6 U U 0.25 29.4 12.5
U U 1 58.8 22.2 U U 1 63.9 24.1 U U 1 38 14.1
U U 2 59.6 20.8 U U 2 63.5 21.5 U U 2 40.3 13.4
U W 0.25 61.3 24.5 U W 0.25 60.6 25 U W 0.25 30.9 12.6
U W 1 60 22.1 U W 1 62 22.4 U W 1 35.1 12.3
U W 2 57 18.5 U W 2 61.7 19.1 U W 2 41 11.4
W U 0.25 63.4 24.7 W U 0.25 60.3 25.1 W U 0.25 29.4 12.6
W U 1 60.1 22.2 W U 1 62.4 23.7 W U 1 35.8 13.8
W U 2 61.7 20.2 W U 2 62.5 21.4 W U 2 40.3 14.1
W W 0.25 62.9 24.6 W W 0.25 61.8 24.9 W W 0.25 31 12.5
W W 1 59 21.9 W W 1 62.4 22.6 W W 1 36.9 12.6
W W 2 59.4 18.8 W W 2 63 19.1 W W 2 44.8 12
Scenario 7 Scenario 8 Scenario 9
U U 0.25 30.2 15.7 U U 0.25 47.4 21.8 U U 0.25 71.8 31.4
U U 1 32.5 16.1 U U 1 48.4 21.5 U U 1 69.4 29.3
U U 2 33.9 16 U U 2 48.8 20 U U 2 73.8 28.5
U W 0.25 27.9 14.6 U W 0.25 46.8 21.5 U W 0.25 65.9 29.1
U W 1 33.2 15 U W 1 48.9 20.9 U W 1 72.5 28
U W 2 35.4 15.1 U W 2 50.2 19.7 U W 2 74.8 24.4
W U 0.25 28.6 15 W U 0.25 45.7 21.4 W U 0.25 65.3 29.6
W U 1 30.7 14.6 W U 1 49.2 22.1 W U 1 69.7 28.8
W U 2 33 15 W U 2 48.1 21.7 W U 2 69.5 25.9
W W 0.25 27.9 14.8 W W 0.25 43.6 21 W W 0.25 68.7 30.8
W W 1 31.9 14.5 W W 1 47.7 21.6 W W 1 72.8 27.7
W W 2 36.6 13.8 W W 2 50.2 20.5 W W 2 73.1 23.3
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Table 3.3: Simulation results: toxicity and efficacy outcomes are both observed 12
weeks. ‘U’ and ‘W’ respectively denotes a conditionally Uniform distribution and
Weibull distribution of toxicity or efficacy TITE. The enrollment of patients follow a
Poisson process, with Rate=0.25, 1, or 2. The estimated probability of selecting the
OBD is summarized in column ‘Select’, and the average number of patients treat at
the OBD is under column ‘Treat’.
Tox Eff Rate Select Treat Tox Eff Rate Select Treat Tox Eff Rate Select Treat
Scenario 1 Scenario 2 Scenario 3
U U 0.25 69.1 29.6 U U 0.25 68.3 26.6 U U 0.25 70.7 27.8
U U 1 73.6 29.2 U U 1 64.8 23.5 U U 1 72.9 27.4
U U 2 71.6 25.7 U U 2 67.1 21.4 U U 2 71.7 25.4
U W 0.25 70.1 29.3 U W 0.25 67.2 26.2 U W 0.25 72.8 28.1
U W 1 73.4 26.7 U W 1 67.2 22.8 U W 1 75.9 27.3
U W 2 77.2 23.8 U W 2 67.5 19 U W 2 72.5 22.8
W U 0.25 68 29.1 W U 0.25 66.5 26 W U 0.25 69.8 27.6
W U 1 68.8 27.2 W U 1 63.9 22.8 W U 1 78.6 29
W U 2 71.3 26.1 W U 2 65.7 20.6 W U 2 72.6 25.1
W W 0.25 67.7 28.3 W W 0.25 68.4 26.2 W W 0.25 69.3 27.2
W W 1 73.2 26.9 W W 1 70.6 23.1 W W 1 74.2 26.4
W W 2 74.4 22.5 W W 2 67.3 17.8 W W 2 73.8 23
Scenario 4 Scenario 5 Scenario 6
U U 0.25 59.2 24.2 U U 0.25 64.6 26.1 U U 0.25 31.4 12.5
U U 1 60.4 22.4 U U 1 60 22.5 U U 1 34.1 12.8
U U 2 61.2 20.2 U U 2 62.5 20.6 U U 2 39.2 12.1
U W 0.25 60.7 24.4 U W 0.25 60.6 24.6 U W 0.25 30.7 12.4
U W 1 61.3 21.8 U W 1 56.5 20.4 U W 1 34.2 11
U W 2 57.9 18.9 U W 2 61.1 16.8 U W 2 39.8 10.1
W U 0.25 61.9 24.5 W U 0.25 60.2 24.8 W U 0.25 31.7 12.9
W U 1 61.5 22.7 W U 1 59.7 22.9 W U 1 32.3 12.4
W U 2 57.7 20.2 W U 2 61.6 19.9 W U 2 39 12.9
W W 0.25 62.3 24.6 W W 0.25 61.1 24.8 W W 0.25 31.8 12.7
W W 1 59.9 21.6 W W 1 62 21.4 W W 1 37.1 11.7
W W 2 58.5 18.7 W W 2 63.7 17.8 W W 2 42.3 10.8
Scenario 7 Scenario 8 Scenario 9
U U 0.25 29.9 15.2 U U 0.25 46.8 21.5 U U 0.25 66.1 29.7
U U 1 31.8 16.8 U U 1 52.5 20.7 U U 1 70.6 30
U U 2 34.6 16.5 U U 2 49 17.9 U U 2 74.2 28.8
U W 0.25 27.5 15.1 U W 0.25 48.8 21.2 U W 0.25 67.5 30
U W 1 31.6 15.5 U W 1 52.2 19.9 U W 1 72.4 28.6
U W 2 40.2 16.7 U W 2 52.4 16.9 U W 2 77.6 25.9
W U 0.25 27.4 14.7 W U 0.25 44.9 22 W U 0.25 67.7 30.4
W U 1 31.8 15.1 W U 1 45.6 21.2 W U 1 70.4 28.7
W U 2 29.9 13.4 W U 2 44.9 19 W U 2 71.2 26.5
W W 0.25 27.4 14.1 W W 0.25 45.1 21.4 W W 0.25 69.7 30.7
W W 1 29.3 13.8 W W 1 49.8 22 W W 1 72.7 27.3
W W 2 36 13.5 W W 2 49.9 18.6 W W 2 73 23.4
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Table 3.4: Distribution of dose selection and patient allocation to each dose level
after 1000 iterations of simulation. ‘U’ and ‘W’ respectively denotes a conditionally
Uniform distribution and Weibull distribution of the toxicity and efficacy TITE vari-
ables. The enrollment of patients follows a Poisson process, with Rate=0.25. Max-
imum sample size is N = 60. The maximum tolerated DLT rate is set at ξ = 33%.
Dose-response scenarios are detailed in Table 3.1.
Scenario Tox Eff Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6
Percentage of final selection
6 U W 0.5 2.4 20 22.1 24.3 30.7
6 U U 0.9 2.4 17.5 24.1 23.7 31.4
6 W U 0.3 2.8 17.6 22.8 24.8 31.7
6 W W 0.6 2.7 17.9 22.6 24.4 31.8
Average number of patient treated
6 U W 2.5 4.6 11.5 13.6 15.4 12.4
6 U U 2.6 4.3 10.8 14.0 15.9 12.5
6 W U 2.4 4.4 11.06 13.3 15.9 12.9
6 W W 2.5 4.3 10.9 13.9 15.7 12.7
Percentage of final selection
7 U W 27.5 27 26.9 17.2 1.4 0
7 U U 29.9 24.4 28.7 16.2 0.8 0
7 W U 27.4 25.6 30.6 15.5 0.9 0
7 W W 27.4 24.4 30.4 16.3 1.5 0
Average number of patient treated
7 U W 15.1 14.9 16.4 11.0 2.3 0.3
7 U U 15.5 15.0 17.0 10.2 2.4 0.3
7 W U 14.7 14.6 17.0 10.8 2.5 0.3
7 W W 14.1 14.5 17.2 10.9 3.0 0.4
dose levels of ATRA, {15, 30, 45 mg/m2}, denoted by d1, d2, d3. To design a study us-
ing the proposed method, we assume dose-toxicity is monotonic and choose toxicity
prior skeleton p = (0.15, 0.25, 0.35). A full class of L = 5 efficacy skeletons can be
constructed as
Q =

0.4 0.3 0.2
0.3 0.4 0.3
0.2 0.3 0.4
0.3 0.4 0.4
0.4 0.4 0.4

.
For this study, we excluded the first two skeletons because we do not expect
52
efficacy to decrease at higher doses. Q is reduced to
Q =

0.2 0.3 0.4
0.3 0.4 0.4
0.4 0.4 0.4
 .
DLTs can be observed within 4 weeks of the treatment while efficacy effects may
take as long as 8 weeks to be observed. If we waited until each patient is fully observed
before we can enroll the next patient, a trial of 35 patients will be impractically
long. However, if we can enroll a patient every two weeks, our proposed method can
shorten the trial duration to 14 months by using partial information obtained from
the patients who are still under observation.
For example, suppose the trial starts with the first patient receiving d1, and no
DLT or efficacy responses are observed when the second patient is enrolled 2 weeks
later. We weight of toxicity outcome from the first patient is given by τ(tj,n, T ) =
arg min(2/4, 1) = 0.5 and the weight of efficacy outcome is τ(tj,n, T ) = arg min(2/8, 1) =
0.25. Applying the standard TITE CRM, we can estimate the probability of DLT
from the lowest dose to the highest dose, that is (0.11, 0.20, 0.29).
According to equation (3.3), the likelihood function for the `th efficacy model can
be expressed as
Lw` (β`|Ω1) = {τj(tj,n, T ) · qexp(β`)`xj }0{1− τj(tj,n, T ) · q
exp(β`)
`xj
}1
= 1− 0.25 · qexp(β`)`xj .
With the likelihood function, we can calculate the posterior model probabilities for
each ` according to equation (3.4). For ` = 1 through ` = 3, w(`|Ωn=1) = 0.339, 0.333,
and 0.327, respectively. The posterior model probabilities are very close to each other
because we only have one observation. According to equation (3.5), the implied best
dose for each model ` = 1, 2, 3 is dose level d3, d2, d1, respectively.
The second patient will be randomized, and the dose assigning probability is
calculated using equation (3.6). The probability of each dose is 0.327, 0.333, and
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0.339. All three dose levels have positive probabilities to be assigned because the
toxicity skeletons and observed data suggest that the estimated risk of DLT at the
highest dose is smaller than the prespecified threshold ξ = 33%.
For the second patient, all 3 models are included in the calculation of dose as-
signing probabilities since the sample is currently very small. As the sample size
increases, we gradually reduce the number of models included in the calculation. The
number of models used in probability calculation can be obtained from equation 3.7.
This process continues until the maximum sample size is reached. The second pa-
tient will have approximately the same probability of receiving each of the candidate
doses. This is intuitively appropriate as we currently do not have enough information
to favor one dose over another and rely mostly on the model skeletons. As shown in
the simulation study, the OBD tends to higher probabilities than the other doses.
For the motivating example, we run simulations and show that the proposed
method has about 50% chance in selecting the OBD under various true dose-response
scenarios with a sample size of 35. The chance of selecting a dose above the true
MTD is less than 10%. We detailed the simulation scenarios and results in Table
3.5. Patient enrollment is assumed to follow a Poisson distribution with rate = 0.5
per week. Time to toxicity and time to efficacy responses are assumed to follow a
conditional uniform distribution. Toxicity and efficacy responses are observed up to
4 and 8 weeks, respectively.
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Table 3.5: Motivating example simulation scenarios and results
TITE Dist’n True (toxicity, efficacy) probability
Scenario 1 (0.05, 0.15) (0.10, 0.30) (0.20,0.45)
Tox-U, Eff-U 9.7 25.9 64.4
Tox-U, Eff-W 9.7 29.7 60.9
Tox-W, Eff-W 9.2 25.2 65.6
Tox-W, Eff-U 8.2 24.6 67.2
Scenario 2 (0.05, 0.15) (0.10, 0.35) 0.20, 0.35)
Tox-U, Eff-U 10.2 48.0 41.8
Tox-U, Eff-W 10.6 49.1 40.3
Tox-W, Eff-W 9.9 48.6 41.5
Tox-W, Eff-U 10.2 47.0 42.8
Scenario 3 (0.05, 0.30) (0.10, 0.30) (0.20, 0.30)
Tox-U, Eff-U 44.5 30.9 24.3
Tox-U, Eff-W 46.3 29.3 24.4
Tox-W, Eff-W 45.0 29.9 25.1
Tox-W, Eff-U 43.5 30.6 25.9
Scenario 4 (0.15, 0.15) (0.30, 0.30) (0.40, 0.30)
Tox-U, Eff-U 35.5 51.8 12.7
Tox-U, Eff-W 36.2 51.8 12
Tox-W, Eff-W 36.5 51.8 11.7
Tox-W, Eff-U 39 48.9 12.1
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3.6 Discussion
In this chapter, we answered the question posed in the Wages and Tait [44] article
about extending the method to situations where binary toxicity and efficacy outcomes
do not occur in a reasonably short time-frame. We outlined the a phase I/II method
that accounts for varying degrees of delayed outcomes for both toxicity and efficacy
of MTAs.
Through extensive simulations, we demonstrated the method’s ability to accu-
rately select the best dose while ensuring all available information is used in assigning
doses to participating patients. The proposed design is most appropriate when non-
monotone dose-efficacy relationship is expected. We also showed the robustness of
the proposed method against various dose finding scenarios, dose-relationships, and
patient recruit rates.
Even though faster patient enrollment will not diminish the accuracy of OBD
selection, it will decrease the number of patients receiving the OBD. Therefore, when
enrollment is very fast, the proposed method may raise ethical concerns. A solution
is to temporarily pause enrollment to accumulate data from the existing patients. It
requires further research to find and test appropriate enrollment restrictions.
Another potential direction for future study is early termination rules. Currently,
the trial will continue until sample size is reached. Early terminations, either for
futility or safety, will further reduce expected trial duration and save resources. In
addition, inefficient/unsafe dose levels may be excluded from the study once enough
patients have been assigned to it.
Copyright c© Donglin Yan, 2018.
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Chapter 4 An R Package for Seamless Phase I/II Adaptive Design Using
Extensions of the Continual Reassessment Method
4.1 Abstract
With the emergence of cytostatic cancer treatments, the paradigm of dose-finding
trials has been shifted. Traditional Phase I trials of cytotoxic agents aim to select the
maximum tolerated dose (MTD) because cytotoxic agents non-selectively attack the
process of cell division and better therapeutic effects can be expected at higher dose
level. Cytostatic agents act through a different mechanism than cytotoxic agents and
the dose-efficacy curve is not necessarily monotonic. Therefore, dose-finding clinical
trials need to incorporate efficacy data in order to address the issue of non-monotonic
dose-response relationships. When designing such dose-finding trials, we need to si-
multaneously protect trial participants from excessive toxicity and treat them at a
therapeutically optimal dose level. Meanwhile, a design is only feasible if it can be
completed within a reasonable time-frame. We proposed new seamleass phase I/II
designs for cytostatic agents such as molecularly targeted agents and biologic ther-
apies. In this chapter, we describe the usage and implementation of the R package
bpocrm. The goal of our R package is to provide a tool for utilization and further
investigation of the proposed designs. The bpocrm package contains functions to
calculate dose-assigning probabilities given accrued data from currently enrolled pa-
tients, make final dose selections at the end of the trial, conduct simulation studies
to evaluate operating characteristics such as probability of correct dose selection and
number of patients treated at the best dose level, and generate plots to illustrate
the dose-finding process. The package can be used for binary endpoints when both
toxicity and efficacy can be observed within a reasonably short time-frame or for
time-to-event endpoints when delayed responses are expected.
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4.2 Introduction
A conventional Phase I oncology trial of chemotherapy agent aims at identifying the
maximum tolerated dose (MTD). The MTD is a dose level beyond which the risk
of severe toxicity outweighs potential therapeutic benefits. The MTD selected from
Phase I will be further evaluated in a subsequent Phase II trial for efficacy. MTD is
determined primarily through toxicity data without considering efficacy. This Phase
I followed by Phase II approach assumes that the MTD is the highest dose with
acceptable toxicity risk and it is also the most promising dose for efficacy. This
assumption is not necessarily plausible for some cytostatic cancer drugs, such as
molecularly targeted agents (MTAs) [54] and biologic therapies, where higher dose
levels do not guarantee increased chance of efficacy. The drug therapeutic effects
could possibly decrease or plateau after exceeding an intermediate dose while toxicity
risk continues to increase. Therefore, the primary goal of this type of trials might
shift to select an optimal biologic dose select the optimal biological dose (OBD) that
is defined as the dose level with the highest probability of efficacy and acceptable risk
of toxicity. A dose-finding design that aims to select the OBD needs to jointly model
toxicity as well as efficacy outcomes.
Several designs have been developed for Phase I/II trials by jointly modeling tox-
icity and efficacy data, including a bivariate CRM design by Braun [38], an adaptive
Bayesian method by Thall et al. that balances trade-offs between the probabilities of
treatment efficacy and toxicity [39], a design that models the odds ratio of toxicity
and efficacy by Yin et al. [41], and an approach proposed by Hoering that identifies
MTD using traditional methods in Phase I and then search for OBD around the
MTD in the following Phase II trials [36], and a design by Wages and Tait [44] that
constructs and evaluates multiple CRM-like models to account for different possible
dose-efficacy curves, among many others.
Even though many recently proposed seamless Phase I/II designs have demon-
58
strated desirable operating characteristics, such as high probability in selecting the
correct dose, there is yet a design that is widely utilized in practice. It takes time
for new designs to be accepted by the other researchers. More importantly, novel
designs need to be accepted not only by statisticians, but also the medical research
community. The CRM design was proposed in early 1990s and only start becoming
a frequently utilized design until recent years [21, 22], even though its statistical su-
periorities have long been recognized by statisticians. The design by Wages and Tait
is by nature an extension of the CRM design, which makes it easier to be accepted
by people who have experience with the CRM. In addition, we proposed a redesign
of the adaptive randomization stage used by the original Wages and Tait design in
Chapter 2 to optimize its performance. We demonstrated through simulations that
the proposed redesign allocates more patients to the OBD while slightly improve the
probability of correct dose selection. We also extended the original design to incor-
porate TITE outcomes to address the issue of delayed outcomes in Chapter 3. The
original design expects both toxicity and efficacy outcomes can be observed within a
short follow-up period, but delayed endpoints are fairly common, especially for effi-
cacy outcomes. The proposed TITE extension addressed this issue and substantially
shorten the total trial duration.
However, there is not a software package available to implement and investigate
this design and its extensions. In this chapter, we introduce an R package, bpocrm
that provides tools for implementing the original Wages and Tait design as well as
the redesigned adaptive randomization stage and TITE extensions. This package also
includes functions to conduct simulation studies and generate plots to demonstrate
the dose-finding process. The rest of this chapter is organized as follows: Section 4.3
describes the original design, redesigned adaptive randomization strategy, and the
TITE extension; Section 4.4 demonstrates the main functions in this package with
various examples; Section 4.5 summarizes the limitations and future development of
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the design and R package.
4.3 Methods
Suppose a trial aims at recommending a dose for further investigation from I pre-
defined dose levels D = {d1, d2, . . . , dI}. When it is plausible to assume a monotonic
dose-efficacy curve, the goal is usually to identify the MTD. For the design by Wages
and Tait [44], it considers the possibility for efficacy to plateau or decrease after an
intermediate dose level, and the goal is to find the OBD. Binary toxicity/efficacy
endpoints, denoted by Yj and Zj, are used when outcomes can be observed within
a reasonably short time-frame. The subscript j = 1, 2, 3, . . . , N is the index of par-
ticipating patient ordered by sequence of enrollment, with N denoting the maximum
sample size.
Yj =

0, if not DLT
1, if DLT
, and Zj =

0, if no efficacy response
1, if observe efficacy response
Dose level administered on the jth subject is denoted by Xj ∈ D. After observing
the response from the first n subjects, the toxicity and efficacy data can be given in
form of Ωj = {(x1, y1, z1), (x2, y2, z2), . . . , (xn, yn, zn)}
When delayed responses are expected, TITE outcomes can be used to utilize
partial information from patients who are still under observation and potentially
shorten the total trial duration. Let tj,n denotes the follow-up time for patient j
by the time the (n + 1)th patient is enrolled. The maximum length of follow-up
time, denoted by T , is the same for each patient. The observed toxicity and efficacy
response, Yj,n and Zj,n are dependent on tj,n. Note that the value of Yj,n and Zj,n may
change from 0 to 1 as n increases, indicating toxicity/efficacy effects manifest after a
certain time point. For each patient, we assume there are unobservable thresholds tTj
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and tEj , only beyond which a positive toxicity or efficacy response can be observed.
Yj,n =

0 (no DLT ) when tj,n < t
T
j
1 (observe DLT ) when tj,n ≥ tTj
, and
Zj,n =

0 (no efficacy) when tj,n < t
E
j
1 (observe efficacy) when tj,n ≥ tEj
.
By the time the (n+ 1)th patient is enrolled, data observed from the first nth patients
can be expressed in form of ΩTn = {(xj, yj,n, zj,n, tj,n)} for j = 1, 2, . . . , n.
The probability of observing a DLT and efficacy response at each dose level is
denoted by piY (di) and piZ(di), respectively.
Modeling Toxicity and efficacy
We assume toxicity monotonically increases with dose levels, and an acceptable dose
range A = {di|pˆiY (di) < ξ} can be obtained by the traditional CRM [15,66] or TITE
CRM [23] depending on the outcome of interest and the time expected to observe
it. Constant ξ is the maximum tolerated DLT rate to be specified by the users. We
utilize the dfcrm package to run traditional CRM or TITE-CRM models. For the
rest of this chapter, we set ξ = 33%. OBD is defined as the dose with the highest
efficacy within the range that still assures safety.
OBD = arg max
di∈A
{piE(di)}.
Since the shape of dose-efficacy curve is unknown, the original Wages and Tait
design [44] proposes to use a class of working models constructed from L = 2× I − 1
efficacy skeletons (2I models will have shapes that plateau or peak at each dose level
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minus one duplicate). Let Q denotes a class of skeletons:
Q =

q1
q2
...
qL

=

q11 q12 q13 . . . q1I
q21 q22 q23 . . . q2I
. . .
qL1 qL2 qL3 . . . qLI

(4.1)
Each row q` ∈ Q is a set of skeletons, denoting a unique shape of the does-efficacy
curves. Note that some rows in Q may be removed if additional information about
the dose-efficacy curve is available. For example, if there it is plausible to assume
that efficacy will not decrease within the range of candidate doses, L−1 rows may be
removed from Q. Elements in of the matrix, q`i ∈ Q, are constants that represents
our initial guesses of the probability of efficacy at dose level i, under the `th working
model. For example, if there are three dose levels, we can construct Q as a 5 by 3
matrix:
Q =

0.3 0.4 0.5
0.4 0.5 0.4
0.5 0.4 0.3
0.4 0.5 0.5
0.5 0.5 0.5

If there efficacy is unlikely to decrease, then Q can be reduced to
Q =

0.3 0.4 0.5
0.4 0.5 0.5
0.5 0.5 0.5
 .
Based on each q`, a unique efficacy working model is constructed as model can be
expressed as
piE(`, di) = Pr(zj = 1|`, di) ≈ G`(xj; β`) = qexp(β`)`i , (4.2)
where piE(di, `) is the estimated probability of observing a efficacy response on a
patient tested at dose level di, and β` is the model parameter. Based on the binary
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efficacy data in Ωn, the likelihood function can be expressed as
L`(β`|Ωn) =
n∏
j=1
{qexp(β`)`xj }
zj{1− qexp(β`)`xj }
1−zj
. (4.3)
Given the TITE data, the likelihood function can be revised to
Lw` (β`|ΩTn ) =
n∏
j=1
{τj(tj,n, T ) · qexp(β`)`xj }Zj,n{1− τj(tj,n, T ) · q
exp(β`)
`xj
}1−Zj,n . (4.4)
where the weight function τE(tj,n, T ) denotes the weight given to the outcome ob-
served from the jth patient by the time n patients have received the treatment. T
is a constant denoting the observation window of the outcomes. τ(tj,n, T ) represents
the proportion of follow-up time completed. For this version of R package, we choose
to use the linear weighting scheme, that is,
τ(tj,n, T ) =

arg min(tj,n/T, 1) if no response observed at tj,n
1 if response observed at tj,n
τ (tj,n, T ) = 1 when tj,n ≥ T , denoting patient j has completed efficacy observation.
The posterior probability distribution and expected value for model parameter β`
can be expressed as follows:
For binary endpints: P`(β`|Ωn) = L`(β`|Ωn)h(β`)∫
β`
L`(β`|Ωn)h(β`)dβ` , (4.5)
βˆ` =
∫
β`
β`L`(β`|Ωn)h(β`)dβ`∫
β`
L`(β`|Ωn)h(β`)dβ` (4.6)
For binary endpints: P`(β`|ΩTn ) =
Lw` (β`|ΩTn )h(β`)∫
β`
Lw` (β`|ΩTn )h(β`)dβ`
, (4.7)
βˆ` =
∫
β`
β`Lw` (β`|ΩTn )h(β`)dβ`∫
β`
Lw` (β`|ΩTn )h(β`)dβ`
(4.8)
In addition, the posterior model probabilities given the observed data can be estab-
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lished as:
For binary endpints: w(`|Ωn) = τ`
∫ L`(β`|Ωn)h(β`)dβ`
L∑`
=1
τ`
∫ L`(β`|Ωn)h(β`)dβ` , (4.9)
For TITE endpints: w(`|ΩTn ) =
p(`)
∫
β`
Lw` (β`|ΩTn )h(β`)dβ`
L∑`
=1
p(`)
∫ Lw` (β`|ΩTn )h(β`)dβ` (4.10)
where τ` is the prior probability that the model built on skeleton q` is the best
model to describe the dose-response relationship. We set τ` = 1/L, assuming no prior
knowledge about the shape of dose-response relationship. Each time a new patient
enters the trial, w(`|Ωn) is updated and all candidate models are re-evaluated and
compared against each other. Given any model ` probability of efficacy response can
be estimated as
pˆiE(di) ≈ G`(di; βˆ`) = qexp(βˆ`)i` , (4.11)
Adaptive randomization
Original Adaptive Randomization: Since w(`|Ωn) is obtained from small sam-
ples, especially in early stage of the trial, we will not rely entirely on the w(`|Ωn)
in selecting the best fit model. The original design would randomize an arbitrary
number of patients, nAR, based on the estimated efficacy probability pˆi(di, `
∗) if the
estimated risk of toxicity is acceptable. Specifically, when n ≤ nAR, we find
`∗ =

arg max{w(`|Ωn)} for binary endpoints
arg max{w(`|ΩTn )} for TITE endpoints
Based on the selected model `∗, acceptable dose range A, and estimated probability of
efficacy piE(di, `
∗), we can randomize the next patient to dose level i with probability
Ri =
pˆiE(di, `
∗)∑
di∈A
pˆiE(di, `∗)
(4.12)
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Modified adaptive randomization: In Chapter 2, we proposed a different
approach to randomize patients by using w(`|Ωn) to weight the implied best dose
from each candidate model. This modified randomization design tends to allocate
more patients to the OBD and improve the chance of correctly selecting the OBD.
In addition, we do not need to specify an arbitrary randomization sample size nAR.
Instead, this method is forced to converge into a final dose as sample size increases.
If a model was built using skeleton q`, then the dose level recommended by this
model can be expressed as S(`), that is
S(`) = min{arg max
i
(piE(di ∈ A, `))}. (4.13)
The dose at level S(`) is expected to have the maximum chance of generating efficacy
response if the shape of dose-efficacy model ` is closest to the true dose-efficacy
relationship. w(`|Ωn) indicates the likelihood of model ` being the most similar one
to the true dose-efficacy curve given the observed data. Instead of selecting the best
fit model-based on w(`|Ωn), we use w(`|Ωn) to weight the dose recommendation from
each model. The dose-assigning probability can be calculated as
R∗i =
R∗∗i
I∑
i=1
R∗∗i
, where R∗∗i =
2I−1∑
i
w(`|Ωn)I(di = S(`) and w(`|Ωn) ≥ w(L−L′+1)).
(4.14)
where I(.) is an indicator function. w(1) ≤ w(2) ≤ · · · ≤ w(L) denote the ordered
posterior model probability w(`|Ωn). Equation (4.14) considers the recommended
dose from L′ best-fit models and weights the recommendations of each model by
w(`|Ωn). When the suggested dose is outside the safety dose range, the highest dose
in A will be used to ensure safety.
The number of models to be considered for patient randomization L′ is gradually
reduced from L to 1 based on the observed sample size.
L′ =
⌈(
N − n
N
)δ
L
⌉
(4.15)
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δ is a constant referred to as the drop rate parameter. When δ = 1, one candidate
model is excluded from calculating the randomization probability for each additional
N/L patients. When 0 < δ < 1, models are dropped at a slower rate when sample
size is small and faster when sample size is large, vice versa for when δ > 1. When
L′ = 1, only the best fit model will be considered and the next enrolled patients
will be randomized to the best dose recommended by the selected model with 100%
probability. We demonstrated in another study that 2 ≤ δ ≤ 3 gives the most
desirable operating characteristics.
4.4 Usage of the package
Package functions
Package bpocrm depends on three libraries: nnet, dfcrm, and binom [67–69].
Package nnet was employed to find the maximum position in a vector. Package
dfcrm was employed to utilize CRM and TITE CRM models for analyzing toxicity
data. The binom package was employed for early stopping rules. The exact binomial
confidence intervals for toxicity and efficacy probabilities are calculated at each dose
level using the binom package.
Package bpocrm contains five functions: get.skel, bpocrm.imp, bpocrmTITE.imp,
bpocrm.sim, and bpocrmTITE.sim. The get.skel function constructs a class of efficacy
skeletons as shown in equation 4.1. Input options are summarized in table 4.1. In
order to get generate a class of efficacy skeletons, the users need to specify the number
of candidate dose levels, and maximum and minimum probability of efficacy within
this dose range. A matrix of efficacy skeletons will be returned with each row rep-
resenting a unique shape of the dose-efficacy curve. Note that the matrix generated
by get.skel is not the only way to construct working efficacy skeletons. The users
may construct their own efficacy skeletons based their specific situations. The option
pos.desc determines whether efficacy can decrease after an intermediate dose level.
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Table 4.1: Input options for function get.skel
Name Role
max.eff
Presumed maximum probability of efficacy within the range
of candidate doses.
min.eff
Presumed minimum probability of efficacy within the range
of candidate doses.
ndose Number of dose levels.
pos.desc
Whether or not efficacy can decrease after an intermediate
dose
Functions bpocrm.imp and bpocrmTITE.imp have several arguments in common.
Both functions calculate dose assigning probabilities given the observed data. The
bpocrm.imp function is appropriate when the data is given in binary form, while
the bpocrmTITE.imp function is designed for TITE outcomes. Input options for
bpocrm.imp and bpocrmTITE.imp are summarized in Table 4.2 and Table 4.3, re-
spectively. Both functions require accrued data to be recorded in vectors (d.obs,
y.obs, and z.obs). Since we assume monotonic dose-toxicity relationship, the toxicity
skeleton also needs to be a vector (p.skel). To account for different shapes of the
dose-efficacy curve, efficacy skeletons (q.skel) need to be given as a matrix. Each row
in matrix q.skel is an efficacy skeleton, representing a potential shape of the dose-
efficacy curve. The users may write their own (q.skel) or use the get.qskel function
to get a generic class of efficacy skeletons.
The ar.strategy option determines which adaptive randomization strategy will be
used. When sample size is small, there is not enough data to select a working efficacy
model, so patients are randomized. When ar.strategy=“Original”, the function will
adopt the original design by Wages and Tait. Under this option, the users also
need to specify the number of patients to be randomized through parameter (n.ar),
and parameter (drop.rate) will be ignored. When ar.strategy =“Modified”, adaptive
randomization is based on equation (4.14). This option requires parameter (drop.rate)
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to be provided. The (drop.rate) parameter is denoted by δ in equation 4.15. It
controls how working candidate models are excluded from the calculation of dose
assigning probabilities. Higher δ values will require less observations to exclude an
additional candidate model during early stage of the trial. We recommend δ = 2
(default) or δ = 3 based on simulation studies. Parameter (n.ar) will be ignored when
ar.strategy=“Modified” as this method does not require an arbitrarily selected sample
size for adaptive randomization. Instead, it gradually exclude lack-of-fit working
models based on the number of observations.
The difference between bpocrm.imp and bpocrmTITE.imp is that the bpocrmTITE.imp
function requires an additional vector (t.obs) to specify the length of follow-up for
each patient. The bpocrmTITE.imp function also requires the maximum follow-up
time for toxicity (max.T.tox ) and efficacy (max.T.eff ).
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Table 4.2: Input options for function bpocrm.imp
Name Role
d.obs
A vector of dose levels assigned to patients. The length of
d.obs must be equal to y.obs and z.obs.
y.obs
Toxicity data: a vector of patient toxicity outcomes; 1
indicates efficacy, 0 otherwise. Length must equal to d.obs
z.obs
Efficacy data: a vector of patient toxicity outcomes; 1
indicates efficacy, 0 otherwise. Length must equal to d.obs
N Total number of patients planned for this trial.
p.skel
Toxicity skeleton. A vector of values for the initial geusses of
toxicity probabilities at each dose level. User may provide a
vector with length equal to the number of dose levels, or use
getprior() function from the dfcrm package.
q.skel
Efficacy skeletons. A matrix of efficacy values. Each row of
the matrix is an efficacy skeleton. Each efficacy skeleton
represents a potential dose-response curve. Function
get.qskel() may be used to generate a generic matrix.
tul
Toxicity upper limit. Maximum probability of toxicity
tolerated.
ell
Efficacy lower limit. Minimum probability of efficacy to
continue the trial.
ar.strategy
Choose from “Original” or “Modified”. “Original” is the
strategy used in original Wages and Tait (2015), and
“Modified” is based on equation (4.14).
n.ar
Number of patients to be randomized if
ar.strategy=“Original”.
drop.rate
The δ parameter in equation 2.12 determining how working
candidate models are excluded from the calculation of dose
assigning probabilities. Higher δ values will require less data
to exclude an additional candidate model during early stage
of the trial. We recommend using δ = 2 or δ = 3 from
simulation results.
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Table 4.3: Input options for function bpocrmTITE.imp
Name Role
. . . Same arguments as function bpocrm.imp
t.obs Length of follow-up time for each patient.
max.T.tox Maximum follow-up time for toxicity outcomes.
max.T.eff Maximum follow-up time for efficacy outcomes.
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Functions bpocrm.sim and bpocrmTITE.sim can be used to conduct simulation
studies, and the input options are summarized in Table 4.4 and Table 4.5. The
input options for these two functions are very similar to function bpocrm.imp and
bpocrmTITE.imp. They are only different in a couple of options. First, function
bpocrm.sim and bpocrmTITE.sim require true probabilities of toxicity (p0) and effi-
cacy (q0) at each dose level, as opposed to the implementation function bpocrm.imp
and bpocrmTITE.imp that read accrued data. Vector (p0) and (q0) need to have
length equal to the number of candidate dose levels. Second, the users need to spec-
ify how many iterations to be simulated through parameter (ntrial). Note that when
ntrial = 1, one trial will be simulated and plots will be automatically generated to
illustrate the dose-finding process. When ntrial > 1, summary statistics are returned
to demonstrate the average performance of the method.
When using the bpocrmTITE.sim function, We assume patients enrollment follows
a Poisson distribution and the users need to specify the rate parameter. In addition,
the minimum time to observe toxicity and efficacy responses may follow a Weibull
distribution or Uniform distribution. This is controlled through option (tox.TITE )
and option (eff.TITE ). Maximum follow-up time for toxicity and efficacy responses
are controlled by (max.T.tox ) and (max.T.eff ) respectively.
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Table 4.4: Input options for function bpocrm.sim
Name Role
p0 True toxicity probabilities at each dose level.
q0 True efficacy probabilities at each dose level.
N Total number of patients planned for each trial.
p.skel
Toxicity skeleton. A vector of values for the initial geusses of
toxicity probabilities at each dose level. User may provide a
vector with length equal to the number of dose levels, or use
getprior() function from the dfcrm package.
q.skel
Efficacy skeletons matrix. Each row of the matrix is an
efficacy skeleton, representing a potential shape of the
dose-efficacy curve.
tul
Toxicity upper limit. Maximum probability of toxicity
tolerated.
ell
Efficacy lower limit. Minimum probability of efficacy to
continue the trial.
ar.strategy
Choose from “Original” or “Modified”. “Original” is the
strategy used in original Wages and Tait (2015), and
“Modified” is based on equation (4.14).
n.ar
Number of patients to be randomized if
ar.strategy=“Original”.
drop.rate
The δ parameter in equation (4.15) determining how
working candidate models are excluded from the calculation
of dose assigning probabilities. Higher δ values will require
less data to exclude an additional candidate model during
early stage of the trial. We recommend using δ = 2 or δ = 3
from simulation results.
start.set
Dose level for the first patients. If length greater than 1, a
random dose will be selected.
ntrial
Number of trials to be simulated. When ntrial=1, a plot is
automatically generated to illustrate the dose-finding
process.
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Table 4.5: Input options for function bpocrmTITE.sim
Name Role
. . . Same arguments as function bpocrm.sim
pt.dist
Patient recruitment rate. The expected number of patients
to be enrolled per week.
tox.TITE
Distribution of toxicity minimum follow up time. Toxicity
responses are only observable after the minimum follow up
time. “U”= Uniform. “W”=Weibull.
eff.TITE
Distribution of efficacy minimum length of follow up.“U”=
Uniform. “W”=Weibull. Efficacy responses are only
observable after the minimum follow up time.
max.T.tox Maximum follow-up time for toxicity outcomes.
max.T.eff Maximum follow-up time for efficacy outcomes.
Examples: assigning dose given observed data
Example 1: use the get.skel() function to generate a generic efficacy skeleton matrix.
Consider a dose-finding trial with I = 6 candidate dose levels, where dose-toxicity
is assumed to be monotone but the shape of true dose-efficacy curve can be mono-
tone, plateau, or peak. Toxicity can be modeled using CRM method with skeleton
p = {0.01, 0.08, 0.15, 0.20, 0.29, 0.36}. This toxicity skeleton is chosen arbitrarily for
demonstration purposes. More functions on the CRM can be found in the dfcrm
package.
In the get.qskel() function, the users specify the maximum/minimum probability
of efficacy response (max.eff, min.eff) within the range of candidate doses and number
of candidate doses (ndose). By default, the get.qskel() function will generate a ma-
trix of efficacy skeletons that represent increasing, plateaued, or peaked dose-efficacy
curves. The efficacy is unlikely to decrease after the intermediate dose, the user may
use option pos.desc=FALSE.
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q.skel=get.qskel(max.eff=0.6, min.eff=0.1, ndose=6) will generate the following effi-
cacy skeletons.
Q =

0.1 0.2 0.3 0.4 0.5 0.6
0.2 0.3 0.4 0.5 0.6 0.5
0.3 0.4 0.5 0.6 0.5 0.4
0.4 0.5 0.6 0.5 0.4 0.3
0.5 0.6 0.5 0.4 0.3 0.2
0.6 0.5 0.4 0.3 0.2 0.1
0.2 0.3 0.4 0.5 0.6 0.6
0.3 0.4 0.5 0.6 0.6 0.6
0.4 0.5 0.6 0.6 0.6 0.6
0.5 0.6 0.6 0.6 0.6 0.6
0.6 0.6 0.6 0.6 0.6 0.6

(4.16)
The users may also manually specify a efficacy skeletons to reflect prior knowledge of
the dose-efficacy curve if such information is available.
Example 2: Consider a trial with maximum sample size N = 64 and I = 6
candidate doses. Toxicity and efficacy outcomes can be observed before the next
patient is enrolled, and the data is in binary form. The hypothetical observed data
is summarized in Table 4.6. We use the skeletons obtained in Example 1. Maximum
acceptable toxicity rate is 33% (tul=0.33). The dose administrated, observed toxicity
outcomes, and observed efficacy outcomes are denoted by the vector d.obs, y.obs,
z.obs, respectively.
> d.obs=c(1, 1, 1, 2, 2, 2, 3, 3, 3, 4)
> y.obs=c(0, 0, 0, 0, 0, 0, 0, 0, 1, 1)
> z.obs=c(0, 0, 0, 0, 0, 0, 0, 1, 0, 1)
In this example, we use the original design by Wages and Tait with ar.strategy=‘Original’,
and n.ar=16.
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> set.seed(580)
> bpocrm.imp(y.obs,z.obs,d.obs,N=64,p.skel=p.skel,q.skel=q.skel,tul=0.33,
ell=0.04, ar.strategy=”Original”,n.ar=16)
Table 4.6: Hypothetical data for R-package examples
Patient number 1 2 3 4 5 6 7 8 9 10
Dose Level 1 1 1 2 2 2 3 3 3 4
y.obs (DLT=1) 0 0 0 0 0 0 0 0 1 1
z.obs (Efficacy) 0 0 0 0 0 0 0 1 0 1
Outputs from the above inputs are summarized into a list of R objects. The dose
randomized to the next patient is in ($dose.assign). Because the current sample size
is 10 and we used n.ar=16, this dose assignment is a result of adaptive randomization,
and the probability each dose is in ($ar.prob). In this example, the next patient will
be treated at the second dose level. The probability of receiving the first, second, and
third dose is 15%, 33%, and 52%, respectively. The other dose levels currently have
0% probability because the estimated probability of toxicity is greater than 33%.
The estimated probability of efficacy is calculated in ($peff.hat). Each row in
($peff.hat) is the estimated probability of efficacy given a particular efficacy skeleton.
In this example, there are 11 efficacy skeletons from which 11 candidate efficacy
models are constructed. Therefore, there are 11 rows in ($peff.hat). Using the first
row in matrix 4.16, we would estimate the probability of efficacy at each dose level
to be 0.08, 0.16, 0.26, 0.36, 0.46, and 0.56, given the observed data. How well each
candidate model fits the observed data is given in the posterior model probability
($postprob.eff).
The exact binomial confidence intervals for toxicity and efficacy at each dose
level are used as early termination rules. Whether or not the trial should to stop for
futility or safety are indicated by ($stopf) and ($stops). In this example, both ($stopf)
and ($stops) equal to 0, so the trial would continue to enroll more patients. Note
that to implement the modified adaptive randomization strategy, we need to change
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the “ar.strategy” argument to “ar.strategy=Modified” and specify the “drop.rate”
parameter.
$dose.assign
[1] 2
$ar.prob
[1] 0.1511697 0.3293778 0.5194525 0.0000000 0.0000000 0.0000000
$ptox.hat
[1] 0.04657312 0.07389260 0.28270437 0.36483626 0.43852408 0.50643940
$peff.hat
[1,] 0.07523605 0.1639289 0.2585277 0.3571782 0.45895543 0.56329579
[2,] 0.09617486 0.1734836 0.2636532 0.3647778 0.47558707 0.36477785
[3,] 0.10546731 0.1805253 0.2739004 0.3850571 0.27390042 0.18052526
[4,] 0.14138954 0.2276751 0.3360188 0.2276751 0.14138954 0.07650311
[5,] 0.25072569 0.3607698 0.2507257 0.1606142 0.09045426 0.04027012
[6,] 0.42203760 0.3101938 0.2128020 0.1309135 0.06600986 0.02047585
[7,] 0.09617486 0.1734836 0.2636532 0.3647778 0.47558707 0.47558707
[8,] 0.10546731 0.1805253 0.2739004 0.3850571 0.38505713 0.38505713
[9,] 0.12329303 0.2052681 0.3113183 0.3113183 0.31131829 0.31131829
[10,] 0.17262097 0.2740086 0.2740086 0.2740086 0.27400860 0.27400860
[11,] 0.25538505 0.2553850 0.2553850 0.2553850 0.25538505 0.25538505
$postprob.eff
[1] 0.171979595 0.151907937 0.140425321 0.057513786 0.014484311 0.006765511
0.151907937 0.140425321 0.088890872 0.044913352 0.030786058
$stopf
[1] 0
$stops
[1] 0
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Example 3:
Consdier the same scenario as Example 2, except we incorporate the time of follow-
up into the design. Toxicity is observed for up to 4 weeks and efficacy is followed up
to 12 weeks. Suppose the first 6 patients have completed follow-up for both toxicity
and efficacy and the last 4 patients have been treated observed for 5, 3, 2, and 1 weeks
respectively. In addition, we use the ar.strategy=“Modified” in this example. Under
the modified adaptive randomization strategy, we do not specify how many patients
are being randomized. Instead, candidate models are gradually eliminated, and the
design would converge into a final dose. In this example, the next patient is assigned
to the third dose level with 95% probability, while dose 2 still has 5% probability.
Function input and results are listed below:
> bpocrmTITE.imp(d.obs,y.obs,z.obs,t.obs, p.skel,q.skel,tul,ell,N=64,
+ ar.strategy=”Modified”,n.ar=1, drop.rate=2,
+ max.T.tox=4, max.T.eff=12)
$dose.assign
[1] 3
$ar.prob
[1] 0.0000000 0.0469965 0.9530035 0.0000000 0.0000000 0.0000000
$ptox.hat
[1] 0.05104337 0.07987554 0.29358235 0.37599762 0.44946180 0.51684218
$peff.hat
[1,] 0.1052235 0.2072460 0.3080942 0.4081873 0.50772270 0.60681585
[2,] 0.1309417 0.2185305 0.3142908 0.4166258 0.52452473 0.41662576
[3,] 0.1436048 0.2283276 0.3271660 0.4389357 0.32716604 0.22832763
[4,] 0.1893360 0.2839540 0.3954236 0.2839540 0.18933598 0.11228211
[5,] 0.2945520 0.4062475 0.2945520 0.1987332 0.11966102 0.05853726
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[6,] 0.4608129 0.3494873 0.2491433 0.1610483 0.08707241 0.03043070
[7,] 0.1309417 0.2185305 0.3142908 0.4166258 0.52452473 0.52452473
[8,] 0.1436048 0.2283276 0.3271660 0.4389357 0.43893567 0.43893567
[9,] 0.1677959 0.2591610 0.3696758 0.3696758 0.36967583 0.36967583
[10,] 0.2176739 0.3250769 0.3250769 0.3250769 0.32507686 0.32507686
[11,] 0.3027060 0.3027060 0.3027060 0.3027060 0.30270597 0.30270597
$postprob.eff
[1] 0.165591398 0.148057056 0.140455613 0.066733860 0.013561551 0.005811805
[7] 0.148057056 0.140455613 0.097269004 0.044709122 0.029297922
Examples of trial simulations
Example 4: In this example, we use the bpocrm.sim() function to simulate one
trial in order to demonstrate the dose-finding process in a trial. Suppose the true
probability of toxicity is p0 = c(0.05, 0.10, 0.20, 0.28, 0.50, 0.50) and probability of
efficacy is q0 = c(0.05, 0.13, 0.25, 0.38, 0.50, 0.63). We use a total of 30 patients to
find locate the OBD which is the 4th dose level. The other options are similar to
Example 2, and we have the following input for the bpocrm.sim() function:
> result= bpocrm.sim(p0,q0,p.skel=p.skel,q.skel=q.skel,
+ tul=0.33,ell=0.04,N=30,start.comb=1,
+ ar.strategy=”Modified”,n.ar=1,drop.rate=2,ntrial=1)
The output is a list containing the true probability of toxicity ($True.tox), true
probability of efficacy ($True.eff), dose level assigned to each patient ($d.obs), ob-
served toxicity ($y.obs) and efficacy ($z.obs) responses. In this example, because we
set ntrial=1, plots are generated to demonstrate the dose-finding process. Specifi-
cally, in Figure 4.1, it shows the dose level (y-axis) received by each patient (x-axis).
Ae shown in the plot, most patients are treated at the 4th dose level, which is the
true OBD. The second most frequently selected dose is the 3rd dose level. The other
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dose levels are only explored with a small number of patients.
If we set ar.strategy=“Modified” as specified in this example, another plot is
generated showing the how candidate models are eliminated (see Figure 4.2). A solid
dot indicates that the corresponding model is included in the calculation of dose
assigning probabilities. As shown in the plot, all models are initially included. By
the 10th patient, models based on the 5th and 6th rows in efficacy skeleton matrix
are excluded. Note that this exclusion is only temporary, each model is re-evaluated
as new data are observed. Towards the end of the trial, only one efficacy model is
considered for dose-assigning, indicating a final dose-efficacy model is selected. The
final model is based on the 3rd row in the efficacy skeleton matrix.
Figure 4.1: An example of treated patient toxicity and efficacy outcomes during one
trial scenario.
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Figure 4.2: Illustration of the model selection process during a simulated trial in
Example 4. A solid point indicates the corresponding model is included in the dose-
assignment process.
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Example 5: Similiar to example 4, except the data is observed in TITE format,
and we repeat the simulation for 100 times. The time to toxicity or efficacy event
follows a Uniform (tox.TITE=“U”) or Weibull (eff.TITE=“W”) distribution. In this
example, we assume that toxicity is followed up to 4 weeks (max.T.tox=4) and efficacy
is monitored up to 12 weeks (max.T.eff=12). In addition, the patient enrollment
follows a Poisson distribution (pt.dist=“P”) with 2 patients per week on average
(pt.rate=2).
> bpocrmTITE.sim(p0,q0,p.skel,q.skel,tul=0.33,ell=0.05,N=64, start.set=c(1),
+ ntrial=100, ar.strategy=”Modified”, n.ar=64 ,drop.rate=2,
+ max.T.tox=4,max.T.eff=12, pt.rate=2, pt.dist=”P”, tox.TITE=”U”, eff.TITE=”W”)
The result is a list containing true rate of toxicity and efficacy at each dose level
($True.tox and $True.eff), percent of final dose selection ($Selection.pct), average
number of patients treated at each dose level ($Treat.avg), average total trial duration
($total.time), total number of toxicity/efficacy outcomes per trial ($n.tox, $n.eff).
In this example, after repeating the trial for 100 times, 44% of trials selected the
true OBD (the 4th dose, and an average of 18.5 patients were treated at the OBD. On
average, 14.4 patients experienced DLT, and 17.6 patients showed efficacy responses.
The total trial duration is about 44 weeks, assuming a 2 patients per week enrollment
rate.
$True.tox
[1] 0.05 0.10 0.20 0.28 0.50 0.50
$True.eff
[1] 0.05 0.13 0.25 0.38 0.50 0.63
$Selection.pct
[1] 1 22 22 44 11 0
$Treat.avg
[1] 4.65 17.73 15.54 18.46 6.77 0.85
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6 $total.time
[1] 43.93541
$n.tox
[1] 14.4
$n.eff
[1] 17.61
4.5 Discussion
In this chapter, we detailed the usage and implementation of the bpocrm package,
corresponding to the several recently proposed methods and designs. This package
provides functions for calculating dose-assigning probabilities, and conducting simu-
lation studies using a recently proposed dose-finding Phase I/II clinical trial design
method and its extensions. These proposed methods demonstrated desirable oper-
ating characteristics, and this package serves as a tool for utilizing the proposed
designs. Meanwhile, this package is also useful for further development, comparison
and evaluation of relevant Phase I/II designs.
There are several limitations to the current version of the bpocrm package. The
early stopping rules used in the designs are based on exact binomial confidence in-
tervals. Conditions for early terminations are rarely met unless the true probabilities
are extreme. We notice the suggested dose level usually converges to a single dose
during late stage of the trials and adding more patients are very unlikely to change
the dose recommendation. Therefore, in future studies, we would like to investigate
the use of convergence as an early stopping rule.
Another feature that we hope to develop in the future versions is a function to
calculate dose recommendations for all possible outcome scenarios in the next 3-5
patients. This feature can make model-based designs more like rule-based designs,
which makes it easier to be implemented in practice.
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In summary, the functions included in this R package can be utilized to implement
and simulate the seamless Phase I/II design proposed in the Wages and Tait (2015)
paper. We also modified the original adaptive randomization stage to improve dose
selection accuracy and allocate more patients to the best dose. By extending the
original design to incorporate TITE outcomes, we addressed the potential issue of
delayed outcomes and long follow-up time. The simulation functions in this package is
a convenient tool for exploring the operating characteristics of the proposed methods
under various scenarios. We plan to submit this package to CRAN shortly after the
completion of this dissertation so that all functions and codes are freely available. All
necessary functions are also available upon request.
Copyright c© Donglin Yan, 2018.
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Chapter 5 Summary and Discussion
5.1 Summary
Phase I dose-finding trials aim to select the most promising dose with an acceptable
toxicity profile for future investigation. When testing cytostatic agents, such as pro-
tein inhibitor, angiogenesis inhibitor or receptor modulator, the shape of dose-efficacy
curve is not necessarily monotonic. Therefore, the trial design should not only ensure
safety, but also incorporate information from efficacy outcomes. In this dissertation,
we completed three aims: 1, we redesigned the adaptive randomization stage used
in the original Wages and Tait (2015) method, and used simulations to show that
the proposed method improves the probability of selecting the correct dose, and allo-
cates more patients to the correct dose during adaptive randomization stage; 2, We
extended the Wages and Tait design to incorporate TITE outcomes. This extension
solved a potential issue of delayed outcomes, which is frequently encountered in prac-
tice; 3, We introduced an R package to provide tools for implementing and simulating
both the original design as well as the proposed extensions.
Aim 1: Re-designed adaptive randomization for the Wages and Tait method
We proposed and evaluated three alternative randomization strategies for a recently
published seamless phase I/II adaptive design. The original design by Wages and Tait
in 2015 was proposed for trials of molecularly targeted agents in cancer treatments.
The proposed randomization strategies calculate randomization probabilities using
the likelihood of every candidate model as opposed to the original design, which
selects the best model and then randomize based on estimations from the selected
model. Through simulations under various scenarios, we evaluated the proposed
randomization strategies and compared them to the original design. The simulation
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results showed that one of the proposed strategies allocates more patients to the OBD
while maintaining approximately the same level of accuracy in selecting the optimal
dose without increasing the overall risk of toxicity.
Aim 2: Bivariate Generalization of the TITE CRM
We developed a seamless phase I/II design for delayed toxicity and efficacy response,
where dose-toxicity is strictly increasing but the shape of dose-efficacy curve can be
increasing, peak, or plateau.
In this design, toxicity and efficacy are modeled in parallel and collected as TITE
endpoints. Toxicity and efficacy data are collected as TITE endpoints. The primary
goal is to optimize the number of patients allocated to the OBD at which the chance
of observing efficacy response is maximized but the risk of DLT is maintained below
a prespecified level. This design combined features of time-to-event (TITE) CRM
and partial order (PO) CRM.
This design is an extension of an existing seamless design proposed by Wages
and Tait [44]. By modeling TITE endpoints instead of binary, this design allows
enrollment of new patients while some patients are still under observation. Toxicities
are monitored by TITE-CRM, and efficacy is monitored by evaluating and weighting a
class of efficacy working models. Since the dose-efficacy relationship is not necessarily
monotonic, our design will construct multiple dose-efficacy models, with each model
representing a unique dose-efficacy shape. The posterior probabilities of each model
being the best-fit will be calculated. When there are not enough data to consistently
and reliably select the best fit-model, patients will be randomized within an acceptable
dose range. The length of time each patient has been followed through the trial is
incorporated into the weighted likelihood functions.
Simulation studies show that the proposed design greatly shortened the total trial
duration as compared to the original design while maintaining approximately the same
85
chance of correctly selecting the OBD in most scenarios. However, faster recruitment
reduces the number of patients allocated to the OBD because dose assigning decisions
are made with less information at each enrollment.
Aim 3: An R package
This R package serves as a tool for implementing and simulating the proposed designs.
It also provides documentation to the functions used in dissertation. The functions
in this package can be utilized by the biostistician to adaptively calculate the rec-
ommended dose for the next patient. There are also functions available to conduct
or replicate simulation studies in order to further explore the characteristics of the
proposed designs. This package also include functions to implement and simulate the
original method proposed by Wages and Tait (2015) [44].
5.2 Discussion
Strengths
Dose-finding trials are generally evaluated by three operation characteristics: prob-
ability of correct final dose selection, proportion of patients treated at or near the
optimal dose, and total trial duration.
One of the strengths from our research is that all proposed methods are evaluated
by comprehensive simulation studies. Different combinations of true dose-toxicity
and dose-efficacy curves are used to examine the performance of the designs. The
re-designed adaptive randomization stage showed increased chance of correct OBD
selection and more patients treated at the OBD under most scenarios. The only
exception is that when the true dose-efficacy is monotonic increasing, the proposed
adaptive randomization method is more conservative than the original design. The
proposed method has a lower probability of selecting the OBD, but the probability
of selecting the OBD and the next lower dose is the same. This indicates that the
86
final dose selected by the proposed method is likely to the OBD or at least very close
to the OBD.
The proposed TITE extension of the Wages and Tait design answered a question
posed in the original Wages and Tait (2015) article. The original design is most
appropriate when both toxicity and efficacy outcomes can be observed within a rea-
sonably short follow-up window, but delayed outcomes are frequently encountered in
practice, especially for efficacy outcomes. When delays are expected in observation
of outcomes, the original design would not be able to utilize all accrued information.
The TITE extension proposed in our research is an effective solution to address this
practical issue, and makes this design more applicable in practice. Simulation studies
show that the chance of correct OBD selection is similar to the original design, but
the total trial duration can be substantially reduced.
Another strength is that we developed the bpocrm R package to implement both
our proposed methods and the original Wages and Tait design. This user-friendly tool
makes these designs accessible for future implementation in practice. It also provides
a good source of documentation for future research and further improvement.
Limitations and future directions
There are several limitations that we hope to addressed in future research.
For both of the proposed methods, even though there are early stopping rules in
the proposed designs, conditions for early trial termination are rarely met in simula-
tions. This is because the current early termination rules are based on exact binary
confidence intervals which are very wide given we only have few patients at each dose
level. Unless the true scenarios are extreme, these intervals are not very helpful for a
typical dose-finding trial. We noticed that patients enrolled towards the end of trials
are usually assigned to the same dose level, indicating a convergence in dose assign-
ment. A potential direction for future research is to propose and implement early
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termination rules that are based on convergence rather than confidence intervals.
Another limitation shared by both of the proposed methods is the absence of
dose-skipping rules. Consequently, the dose assignment is not stable in the beginning
stage of the trials. We believe that dose-skipping rules are likely to have only a
slight impact of the design performance, but it is a necessary for the design to be
implemented in practice. Dose-skipping rules and other practical modifications can
be added to future versions of the R package.
In the TITE extension of the original design, even though the probability of se-
lecting the OBD is not affected by enrollment rate, the number of patients allocated
to the OBD will be substantially reduced if the time between each enrollment is short.
A plausible explanation is that when patients are recruited fast, there is less infor-
mation available to determine the best dose at each enrollment. On the other hand,
if we halt enrollment until every current patient has finished follow-up, every dose
assignment will be based on full information from the previous cohorts, but the trial
duration will be impractically long. A direction for future research is to investigate
how to control the enrollment rate. A potential solution is to halt enrollment when
the number of patients under observation exceeds a certain threshold.
In conclusion, we redesigned the adaptive randomization stage for a seamless
Phase I/II design proposed by Wages and Tait (2015) and used simulations to show
that this modification improved the performance of the original design under most
scenarios. We further expanded the Wages and Tait design to incorporate TITE
outcomes to utilize partial information from patients who are still under observation.
This extension addressed a practical issue of delayed outcomes. Finally, we introduced
an R package to implement both the original design and the proposed extensions. The
R package also provides tool for simulation studies.
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The methods proposed in this research are valuable additions to the original design,
and R package makes these methods accessible to other researchers.
Copyright c© Donglin Yan, 2018.
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Appendices
Table A1: Full simulation results of tuning the drop rate parameter δ (Chapter 2,
section 2.5). A best dose is defined as the level that has maximum chance of efficacy
while assuring safety, and a good dose is the level with 25% or higher chance of
efficacy while assuring safety. Safety is defined as 33% or lower DLT rate.
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Table A2: Full simulation results of Operating Characteristics (Chapter 2, section
2.5). A best dose is defined as the level that has maximum chance of efficacy while
assuring safety, and a good dose is the level with 25% or higher chance of efficacy
while assuring safety. Safety is defined as 33% or lower DLT rate.
91
92
93
94
95
96
97
98
99
100
101
102
Bibliography
[1] National Center for Health Statistics, Health, United States, 2016: With Chart-
book on Long-term Trends in Health. 2017.
[2] National Cancer Institute, “SEER Cancer Statistics Review,” 2015.
[3] R. Collier, “Legumes, lemons and streptomycin: A short history of the clinical
trial,” CMAJ : Canadian Medical Association Journal, vol. 180, no. 1, pp. 23–24,
2009.
[4] A. Bhatt, “Evolution of Clinical Research: A History Before and Beyond James
Lind,” Perspectives in Clinical Research, vol. 1, no. 1, pp. 6–10, 2010.
[5] Streptomycin in Tuberculosis Trials Committee, “Streptomycin Treatment of
Pulmonary Tuberculosis: A Medical Research Council Investigation,” British
Medical Journal, vol. 2, no. 4582, pp. 769–782, 1948.
[6] T. S. Lawrence, C. Runowicz, S. Turner, and J. L. Wade III, “Critical role of
phase I clinical trials in cancer treatment,” Journal of Clinical Oncology, vol. 15,
no. 2, pp. 853–859, 1997.
[7] B. A. Chabner and T. G. Roberts, “Chemotherapy and the war on cancer,” 2005.
[8] National Cancer Institute, “Common Terminology Criteria for Adverse Events
(CTCAE). Version 4.0.,” 2009.
[9] S. K. Carter, “Study design principles for the clinical evaluation of new drugs as
developed by the chemotherapy programme of the National Cancer Institute,”
in The Design of Clinical Trials in Cancer Therapy (M. Staquet, ed.), 1973.
[10] W. J. Dixon and A. M. Mood, “A Method for Obtaining and Analyzing Sensi-
tivity Data,” Journal of the American Statistical Association, vol. 43, no. 241,
p. 109, 1948.
[11] S. D. Durham, N. Flournoy, and W. F. Rosenberger, “A random walk rule for
phase I clinical trials.,” Biometrics, vol. 53, no. 2, pp. 745–760, 1997.
[12] A. Ivanova, A. Montazer-Haghighi, S. G. Mohanty, and S. D. Durham, “Improved
up-and-down designs for phase I trials.,” Statistics in medicine, vol. 22, no. 1,
pp. 69–82, 2003.
[13] M. Stylianou and D. A. Follmann, “The Accelerated Biased Coin Up-and-Down
Design in Phase I Trials,” Journal of Biopharmaceutical Statistics, vol. 14, no. 1,
pp. 249–260, 2004.
103
[14] C. Le Tourneau, J. J. Lee, and L. L. Siu, “Dose Escalation Methods in Phase I
Cancer Clinical Trials,” JNCI Journal of the National Cancer Institute, vol. 101,
no. 10, pp. 708–720, 2009.
[15] J. O’Quigley, M. Pepe, and L. Fisher, “Continual reassessment method: a prac-
tical design for phase 1 clinical trials in cancer.,” Biometrics, vol. 46, no. 1,
pp. 33–48, 1990.
[16] J. O’Quigley and M. Conaway, “Continual Reassessment and Related Dose-
Finding Designs.,” Statistical science : a review journal of the Institute of Math-
ematical Statistics, vol. 25, no. 2, pp. 202–216, 2010.
[17] S. M. Lee and Y. K. Cheung, “Model Calibration in the Continual Reassessment
Method,” Clinical trials (London, England), vol. 6, no. 3, pp. 227–238, 2009.
[18] E. L. Korn, D. Midthune, T. T. Chen, L. V. Rubinstein, M. C. Christian, and
R. M. Simon, “A comparison of two phase I trial designs,” Statistics in medicine,
vol. 13, no. 18, pp. 1799–1806, 1994.
[19] E. Reiner, X. Paoletti, and J. O’Quigley, “Operating characteristics of the stan-
dard phase I clinical trial design,” Computational Statistics & Data Analysis,
vol. 30, no. 3, pp. 303–315, 1999.
[20] A. Iasonos, A. S. Wilton, E. R. Riedel, V. E. Seshan, and D. R. Spriggs, “A
comprehensive comparison of the continual reassessment method to the standard
3 + 3 dose escalation scheme in Phase I dose-finding studies,” Clinical Trials,
vol. 5, no. 5, pp. 465–477, 2008.
[21] M.-K. Riviere, C. Le Tourneau, X. Paoletti, F. Dubois, and S. Zohar, “Designs
of drug-combination phase I trials in oncology: a systematic review of the liter-
ature,” Annals of Oncology, vol. 26, no. 4, pp. 669–674, 2015.
[22] C. Chiuzan, J. Shtaynberger, G. A. Manji, J. K. Duong, G. K. Schwartz,
A. Ivanova, and S. M. Lee, “Dose-finding designs for trials of molecularly targeted
agents and immunotherapies.,” Journal of biopharmaceutical statistics, vol. 27,
no. 3, pp. 477–494, 2017.
[23] Y. K. Cheung and R. Chappell, “Sequential Designs for Phase I Clinical Trials
with LateOnset Toxicities,” Biometrics, vol. 56, no. 4, pp. 1177–1182, 2000.
[24] J. Babb, A. Rogatko, and S. Zacks, “Cancer phase I clinical trials: Efficient
dose escalation with overdose control,” Statistics in Medicine, vol. 17, no. 10,
pp. 1103–1120, 1998.
[25] D. H. Leung and Y. Wang, “Isotonic designs for phase I trials.,” Controlled
clinical trials, vol. 22, no. 2, pp. 126–138, 2001.
104
[26] Y. Yuan, K. R. Hess, S. G. Hilsenbeck, and M. R. Gilbert, “Bayesian Optimal
Interval Design: A Simple and Well-Performing Design for Phase I Oncology Tri-
als.,” Clinical cancer research : an official journal of the American Association
for Cancer Research, vol. 22, no. 17, pp. 4291–4301, 2016.
[27] A. R. Reynolds, “Potential Relevance of Bell-Shaped and U-Shaped Dose-
Responses for the Therapeutic Targeting of Angiogenesis in Cancer,” Dose-
Response, vol. 8, no. 3, pp. 253–284, 2010.
[28] G. Klement, S. Baruchel, J. Rak, S. Man, K. Clark, D. J. Hicklin, P. Bohlen,
and R. S. Kerbel, “Continuous low-dose therapy with vinblastine and VEGF
receptor-2 antibody induces sustained tumor regression without overt toxicity.,”
The Journal of clinical investigation, vol. 105, no. 8, pp. R15–24, 2000.
[29] M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh,
N. Leighl, J. Mezger, V. Archer, N. Moore, and C. Manegold, “Phase III trial
of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line
therapy for nonsquamous non-small-cell lung cancer: AVAil.,” Journal of clinical
oncology : official journal of the American Society of Clinical Oncology, vol. 27,
no. 8, pp. 1227–1234, 2009.
[30] M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh,
N. Leighl, J. Mezger, V. Archer, N. Moore, and C. Manegold, “Overall survival
with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for
nonsquamous non-small-cell lung cancer: results from a randomised phase III
trial (AVAiL).,” Annals of oncology : official journal of the European Society for
Medical Oncology, vol. 21, no. 9, pp. 1804–1809, 2010.
[31] A. Sandler, R. Gray, M. C. Perry, J. Brahmer, J. H. Schiller, A. Dowlati, R. Lilen-
baum, and D. H. Johnson, “Paclitaxel-carboplatin alone or with bevacizumab
for non-small-cell lung cancer.,” The New England journal of medicine, vol. 355,
no. 24, pp. 2542–2550, 2006.
[32] C. Aghajanian, S. V. Blank, B. A. Goff, P. L. Judson, M. G. Teneriello, A. Hu-
sain, M. A. Sovak, J. Yi, and L. R. Nycum, “OCEANS: a randomized, double-
blind, placebo-controlled phase III trial of chemotherapy with or without beva-
cizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary
peritoneal, or fallopian tube cancer.,” Journal of clinical oncology : official jour-
nal of the American Society of Clinical Oncology, vol. 30, no. 17, pp. 2039–2045,
2012.
[33] J. E. Kurtz, A.-C. Hardy-Bessard, M. Deslandres, S. Lavau-Denes, R. Largillier,
C. Roemer-Becuwe, B. Weber, C. Guillemet, D. Paraiso, and E. Pujade-Lauraine,
“Cetuximab, topotecan and cisplatin for the treatment of advanced cervical can-
cer: A phase II GINECO trial.,” Gynecologic oncology, vol. 113, no. 1, pp. 16–20,
2009.
105
[34] O. Engebraaten, H. Edvardsen, E. Lokkevik, B. Naume, V. Kristensen, L. Ottes-
tad, and V. Natarajan, “Gefitinib in Combination with Weekly Docetaxel in
Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results
from a Randomized Phase II Clinical Trial.,” ISRN oncology, vol. 2012, p. 176789,
2012.
[35] A. Manji, I. Brana, E. Amir, G. Tomlinson, I. F. Tannock, P. L. Bedard, A. Oza,
L. L. Siu, and A. R. Abdul Razak, “Evolution of clinical trial design in early drug
development: Systematic review of expansion cohort use in single-agent phase i
cancer trials,” Journal of Clinical Oncology, vol. 31, no. 33, pp. 4260–4267, 2013.
[36] A. Hoering, A. Mitchell, M. LeBlanc, and J. Crowley, “Early phase trial design
for assessing several dose levels for toxicity and efficacy for targeted agents.,”
Clinical trials (London, England), vol. 10, no. 3, pp. 422–9, 2013.
[37] G. Yin, S. Zheng, and J. Xu, “Two-stage dose finding for cytostatic agents in
phase I oncology trials,” Statistics in Medicine, vol. 32, no. 4, pp. 644–660, 2013.
[38] T. M. Braun, “The bivariate continual reassessment method. extending the CRM
to phase I trials of two competing outcomes.,” Controlled clinical trials, vol. 23,
no. 3, pp. 240–56, 2002.
[39] P. F. Thall and J. D. Cook, “Dose-finding based on efficacy-toxicity trade-offs.,”
Biometrics, vol. 60, no. 3, pp. 684–93, 2004.
[40] B. Nebiyou Bekele and Y. Shen, “A Bayesian Approach to Jointly Modeling Tox-
icity and Biomarker Expression in a Phase I/II DoseFinding Trial,” Biometrics,
vol. 61, no. 2, pp. 343–354, 2005.
[41] G. Yin, Y. Li, and Y. Ji, “Bayesian dose-finding in phase I/II clinical trials using
toxicity and efficacy odds ratios.,” Biometrics, vol. 62, no. 3, pp. 777–84, 2006.
[42] W. Zhang, D. J. Sargent, and S. Mandrekar, “An adaptive dose-finding design
incorporating both toxicity and efficacy.,” Statistics in medicine, vol. 25, no. 14,
pp. 2365–2383, 2006.
[43] Y. Yuan and G. Yin, “Bayesian dose finding by jointly modelling toxicity and
efficacy as time-to-event outcomes,” Journal of the Royal Statistical Society.
Series C: Applied Statistics, vol. 58, no. 5, pp. 719–736, 2009.
[44] N. A. Wages and C. Tait, “Seamless Phase I/II Adaptive Design for Oncology
Trials of Molecularly Targeted Agents,” J Biopharm Stat, vol. 25, no. 5, pp. 903–
920, 2015.
[45] M.-K. Riviere, Y. Yuan, J.-H. Jourdan, F. Dubois, and S. Zohar, “Phase
I/II dose-finding design for molecularly targeted agent: Plateau determina-
tion using adaptive randomization,” Statistical Methods in Medical Research,
p. 096228021663176, 2016.
106
[46] M. Gasparini and J. Eisele, “A curve-free method for phase I clinical trials.,”
Biometrics, vol. 56, no. 2, pp. 609–615, 2000.
[47] Y. Zang, J. J. Lee, and Y. Yuan, “Adaptive Designs for Identifying Optimal
Biological Dose for Molecularly Targeted Agents,” Clinical trials (London, Eng-
land), vol. 11, no. 3, pp. 319–327, 2014.
[48] N. A. Wages, M. R. Conaway, and J. O’Quigley, “Continual reassessment method
for partial ordering,” Biometrics, vol. 67, no. 4, pp. 1555–1563, 2011.
[49] Y. Yuan, H. Q. Nguyen, and P. F. Thall, Bayesian designs for phase I-II clinical
trials. Boca Raton, FL: Chapman and Hall/CRC, first edition ed., 2016.
[50] N. A. Wages, C. A. Portell, M. E. Williams, M. R. Conaway, and G. R. Petroni,
“Implementation of a model-based design in a phase 1b study of combined tar-
geted agents,” Clinical Cancer Research, 2017.
[51] N. A. Wages, C. L. J. Slingluff, and G. R. Petroni, “Statistical controversies
in clinical research: early-phase adaptive design for combination immunothera-
pies.,” Annals of oncology : official journal of the European Society for Medical
Oncology, vol. 28, no. 4, pp. 696–701, 2017.
[52] B. Storer, “Design and analysis of phase I clinical trials,” Biometrics, vol. 45,
no. 3, pp. 925 – 937, 1989.
[53] A. Ivanova, “Escalation, group and A + B designs for dose-finding trials,” Statis-
tics in Medicine, vol. 25, no. 21, pp. 3668–3678, 2006.
[54] F. Li, C. Zhao, and L. Wang, “Molecular-targeted agents combination therapy for
cancer: Developments and potentials,” International Journal of Cancer, vol. 134,
no. 6, pp. 1257–1269, 2014.
[55] S. J. Mandrekar, R. Qin, and D. J. Sargent, “Model-based phase I designs in-
corporating toxicity and efficacy for single and dual agent drug combinations:
methods and challenges.,” Statistics in medicine, vol. 29, no. 10, pp. 1077–83,
2010.
[56] F. Donate, G. C. Parry, Y. Shaked, H. Hensley, X. Guan, I. Beck, Z. Tel-Tsur,
M. L. Plunkett, M. Manuia, D. E. Shaw, R. S. Kerbel, and A. P. Mazar, “Phar-
macology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): ob-
servation of a U-shaped dose-response curve in several preclinical models of an-
giogenesis and tumor growth.,” Clinical cancer research : an official journal of
the American Association for Cancer Research, vol. 14, no. 7, pp. 2137–2144,
2008.
[57] P. Khalili, A. Arakelian, G. Chen, M. L. Plunkett, I. Beck, G. C. Parry, F. Do-
nate, D. E. Shaw, A. P. Mazar, and S. A. Rabbani, “A non-RGD-based integrin
binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.,”
Molecular cancer therapeutics, vol. 5, no. 9, pp. 2271–2280, 2006.
107
[58] K. L. van Golen, L. Bao, G. J. Brewer, K. J. Pienta, J. M. Kamradt, D. L.
Livant, and S. D. Merajver, “Suppression of Tumor Recurrence and Metastasis
by a Combination of the PHSCN Sequence and the Antiangiogenic Compound
Tetrathiomolybdate in Prostate Carcinoma,” Neoplasia (New York, N.Y.),
vol. 4, no. 5, pp. 373–379, 2002.
[59] O. Stoeltzing, W. Liu, N. Reinmuth, F. Fan, G. C. Parry, A. A. Parikh, M. F.
McCarty, C. D. Bucana, A. P. Mazar, and L. M. Ellis, “Inhibition of integrin
alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU
infusion reduces colorectal liver metastases and improves survival in mice.,” In-
ternational journal of cancer, vol. 104, no. 4, pp. 496–503, 2003.
[60] J. O’Quigley and S. Zohar, “Retrospective robustness of the continual reassess-
ment method.,” Journal of biopharmaceutical statistics, vol. 20, no. 5, pp. 1013–
1025, 2010.
[61] R. K. Jain, J. J. Lee, D. Hong, M. Markman, J. Gong, A. Naing, J. Wheler,
and R. Kurzrock, “Phase I oncology studies: evidence that in the era of targeted
therapies patients on lower doses do not fare worse.,” Clinical cancer research
: an official journal of the American Association for Cancer Research, vol. 16,
no. 4, pp. 1289–1297, 2010.
[62] T. Schenk, S. Stengel, and A. Zelent, “Unlocking the potential of retinoic acid in
anticancer therapy.,” British journal of cancer, vol. 111, no. 11, pp. 2039–2045,
2014.
[63] S. Lonial, B. M. Weiss, S. Z. Usmani, S. Singhal, A. Chari, N. J. Bahlis,
A. Belch, A. Y. Krishnan, R. A. Vescio, M.-V. Mateos, A. Mazumder, R. Z.
Orlowski, H. J. Sutherland, J. Blade, E. C. Scott, H. Feng, I. Khan, C. M. Uh-
lar, T. Ahmadi, and P. M. Voorhees, “Phase II study of daratumumab (DARA)
monotherapy in patients with 3 lines of prior therapy or double refractory multi-
ple myeloma (MM): 54767414MMY2002 (Sirius).,” Journal of Clinical Oncology,
vol. 33, no. 18 suppl, pp. LBA8512–LBA8512, 2015.
[64] B. Guo and Y. Yuan, “Bayesian Phase I/II Biomarker-based Dose Finding for
Precision Medicine with Molecularly Targeted Agents,” Journal of the American
Statistical Association, vol. 112, no. 518, pp. 0–0, 2016.
[65] T. M. Braun, “Generalizing the TITE-CRM to adapt for early- and late-onset
toxicities,” Statistics in Medicine, vol. 25, no. 12, pp. 2071–2083, 2006.
[66] Y. Cheung, Dose Finding by the Continual Reassessment Method. 2011.
[67] W. N. Venables and B. D. Ripley, Modern Applied Statistics with S. New York:
Springer, fourth ed., 2002. ISBN 0-387-95457-0.
[68] K. Cheung, dfcrm: Dose-finding by the continual reassessment method, 2013. R
package version 0.2-2.
108
[69] S. Dorai-Raj, binom: Binomial Confidence Intervals For Several Parameteriza-
tions, 2014. R package version 1.1-1.
109
Vita
Education
PhD candidate Epidemiology and
Biostatistics
2014 - present
University of Kentucky
Lexington, KY.
M.S. Statistics 2012 - 2014
Kansas State University
Manhattan, KS.
B.S. Mathematics 2010 - 2012
Northern Arizona University
Flagstaff, AZ.
Professional Experience
Graduate Research Assistant 2016 - present
Markey Cancer Center
University of Kentucky
Lexington, KY.
Graduate Teaching Assistant 2015 - 2016
College of Public Health
University of Kentucky
Lexington, KY.
Research Assistant 2014 - 2015
Center for Health Service and
Research
College of Public Health
University of Kentucky
Lexington, KY.
Research Assistant 2013 - 2014
Applied Statistics Lab
Kansas State University
Manhattan, KS.
Graduate Teaching Assistant 2012 - 2013
Department of Statistics
Kansas State University
Manhattan, KS.
110
Award and Certificates
Travel Grant 2016
University of Kentucky
SAS Advanced Programmer
Certificate
2014
SAS institute
Presentation Award 2012
Northern Arizona University
Vesto M. Slipher Scholarship 2011
Northern Arizona University
Publications
1. (In Revision) Yan, D., Wages, N. A., Tait, C., Kindwall-Keller, T., &
Dressler, E. V. Bivariate Generalization of the Time-to-Event Continual
Re- assessment Method. Journal of the Royal Statistical Society. Series C:
Applied Statistics Royal Statistical Society.
2. (In Revision) Yan, D., Wages, N., Dressler, V. Improved Adaptive
Randomization Strategies for the Multidimensional CRM in Phase I/II
Trials. Journal of Biopharmaceutical Statistics.
3. Book Contribution: (2017). Dressler, E. V., & Yan, D. (2017).
Model-Based Designs for Safety In Handbook of Methods for Designing,
Monitoring, and Analyzing Dose Finding Trials. In J. OQuigley, A.
Iasonos, & B. Bornkamp (Eds.). Chapman and Hall/CRC.
4. (In press) Patel, R., Maxwell, S., Yan, D., Dressler, E., Romond, E.,
Mathew A. (2017) Medical Oncologists Perception of Anti-Estrogen
Therapy Benefit in Premenopausal Women with Hormone
Receptor-Positive Early Breast Cancer. Annuals of Internal Medicine.
5. Hough, A. R., Nechols, J. R., McCornack, B. P., Margolies, D. C.,
Sandercock, B. K., Yan, D., Murray, L. (2016). The Effect of Temperature
and Host Plant Resistance on Population Growth of the Soybean Aphid
Biotype 1 (Hemiptera: Aphididae). Environmental Entomology, 1(1),
nvw160. http://doi.org/10.1093/ee/nvw160
6. Fanucchi, L., Yan, D., & Conigliaro, R. L. (2016). Duly noted: Lessons
from a two-site intervention to assess and improve the quality of clinical
documentation in the electronic health record. Applied Clinical
Informatics, 7(3), 653659. http://doi.org/10.4338/ACI-2016-02-CR-0025
111
